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ABSTRACT 
With advances in biotechnology, bioengineering, and chemistry, a wide 
variety of new, more potent and specific active molecules are being created. 
Because of common problems such as low solubility, high potency, and/or 
poor stability of many of these new molecules, the means of drug delivery 
can impact efficacy and potential for commercialization as much as the 
nature of the molecule itself. the controlled release systems (DDS’s) are one 
of the most promising technologies to solve these problems because offer 
several potential advantages over traditional methods of administration. First, 
drug release rates can be tailored to the needs of a specific application; for 
example, providing a constant rate of delivery or pulsatile release. Second, 
DDS provide protection of drugs, especially proteins, that are otherwise 
rapidly destroyed by the body. Finally, DDS can increase patient comfort and 
compliance by replacing frequent (e.g., daily) doses with infrequent (once per 
month or less) injection. the last twenty years the DDS in addition to being 
used for the release of drugs are also used in the field of tissue engineering 
for controlled release of specific molecules, such as growth factors or 
cytokines. 
In the first chapter of this thesis the drug delivery systems have been 
investigate for the control of the concentration of signal molecules within 
tridimensional scaffold for the induction of angiogenesis in bone regeneration 
processes. To achieve a good bone tissue regeneration is essential to have a 
three dimensional structure, called scaffold, with specific physical and 
mechanical properties, such as high porosity, high interconnected pore 
network, high biocompatibility but especially capable of releasing in a 
controlled way bioactive molecules such as proangiogenic factors (VEGF). 
For this reason we have developed a bottom up approach founded on the 
assembly of building blocks by solvent induced microparticle sintering to 
realize multifunctional polymer scaffolds with predefined pore dimension 
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and fully percolative pathway, able to include interspersing DDS for the 
release of angiogenic factor or similar molecules. This approach offers the 
possibility to realize scaffolds that not only meet all the requirements in terms 
of controlled microstructure, chemical stability and mechanical response 
necessary to support neo-tissue growth, but also provide a guidance of cell 
and tissue processes by presenting bioactive agents in a predefined chrono-
programmed manner.  
In the second chapter of this thesis has been developed intraocular drug 
delivery systems for the controlled release of growth factors for the treatment 
of different ocular diseases. The traditional treatment of these pathologies 
consists of daily administration of drugs but, the main limit of these 
conventional treatments is bound to the fact that blood levels of the drug 
falling into the therapeutic range are obtained right after administration. In 
other words, there is a risk that the drug action lasts too little to have a 
significant effect on the patient.  
To overcome this issues and to optimize the clinical performance we have 
developed PLGA micro e nanoparticles system for the controlled release of 
specific factor: Nerve Growth Factor (NGF) to humor vitreous. This factor 
has been shown to have a protective effect on the cells of the visual system, 
opening interesting therapeutic prospects for degenerative diseases currently 
no effective treatments, such as the age-related macular degeneration, 
diabetic retinopathy, retinitis pigmentosa and glaucoma. 
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1. Time Controlled Delivery System 
One of the main lines of research in the field of pharmaceutical technology 
concerns the development of formulations that can release drugs in the body 
in amounts and at controlled rates. There are already numerous 
pharmaceutical forms from which the release can be delayed, or by which the 
speed and duration of release of the active molecules can be programmed. 
That formulations are defined controlled release systems (DDS’s) and allow 
the adjusting the blood level of the drug, in order to avoid phenomena of 
under or over dosing and minimize unwanted side effects.  
The use of this DDS’s can provide several advantages over traditional 
methods of administration. First, drug release rates can be tailored to the 
needs of a specific application; for example, providing a constant rate of 
delivery or pulsatile release. Second, DDS’s provide protection of drugs, 
especially proteins, that are otherwise rapidly destroyed by the body. Finally, 
DDS’s can increase patient comfort and compliance by replacing frequent 
(e.g., daily) doses with infrequent (once per month or less) injection.  
However, there are potential disadvantages that should not be overlooked. 
Disadvantages of using such delivery systems include possible toxicity of the 
materials used, dose dumping, requirement of surgical procedures to implant 
or remove the system, and higher manufacturing costs. DDS main advantages 
and disadvantages are summarized in Table 1.  
A large number of classes of drugs that include chemotherapeutic drugs
1
, 
immunosuppressant’s2, anti-inflammatory agents3,4, antibiotics5,6, opioid 
antagonists
7
, steroids
8,9
, hormones
10
 can benefit from temporal or distribution 
controlled release. Recently, the need to develop new controlled release 
strategies has been intensified by advances in the design of peptide drugs and 
the use of growth factors in therapy. 
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DDS advantages DDS disadvantages 
Extension of the duration of action 
and bioavailability of the drug 
Possibility of toxicity of the materials 
Minimization of drug degradation and 
loss 
Harmful degradation products 
Prevention of drug’s adverse side-
effects 
Necessity of surgical intervention either on 
systems application or removal 
Reduction of dosing frequency Patients discomfort with DDS device usage 
Minimization of drug concentration 
fluctuations in plasma level 
High cost of final product 
Improved drug utilization 
Improved patient compliance 
Table 1 : DDS advantages and disadvantages 
DDS can be produced by using natural or synthetic polymers, which can be 
biodegradable or non-biodegradable (see Fig. 1). These polymeric systems 
can be used in the release of drugs, proteins and cells. 
 
Figure 1 : Type of Polymer used for DDS production 
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The polymers used in DDS should present a set of properties that make them 
suitable materials to interact with the human body, but the biodegradability is 
one of the most important features. Biodegradable polymers are particularly 
attractive for application in DDS since, once introduced into the human body, 
they do not require removal or additional manipulation. Their degradation 
products are normal metabolites of the body or products that can be 
metabolized and easily cleared from the body
11,12
. 
Moreover, synthetic polymers offer a wide variety of compositions with 
adjustable properties. These materials open the possibility of developing new 
DDS with specific properties (chemical, interfacial, mechanical and 
biological) for a given application, simply by changing the building blocks or 
the preparation technique. 
1.1. PLGA Drug Delivery System 
 
Poly(D,L-lactic-co-glycolide), PLGA and its various derivatives have been 
the center focus for developing nano/microparticles encapsulating therapeutic 
drugs in DDS applications
1,4,5,7
 due to their inherent advantages over the 
conventional devices that include extended release rates up to days, weeks or 
months, in addition to their biocompatibility/biodegradability and ease of 
administration via injection.  
 
Figure 2: PLGA Structure 
Macromolecular drugs such as proteins, peptides, genes, vaccines, antigens, 
human growth factors, etc., are successfully incorporated into PLGA or 
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PLGA based nano/microparticles. Despite the formulations already available 
in the market, yet research in this area has advanced greatly due to the 
advantages of PLGA polymers over other systems. Also, the American Food 
and Drug Administration (FDA) have approved a very large number of drug 
delivery products based on this biomaterial. Table 2 lists injectable PLGA 
depots marketed in the US 
13
. Controlled drug release can be easily achieved 
by adjusting the polymer parameters such as molecular weight, monomer 
ratio, drug loading, excipient loading, glass transition temperature, and 
several other formulation variables. These advantages have also led to 
various medical and pharmaceutical applications including sutures, dental 
repairs, fracture fixation, ligament reconstruction, vascular grafts, and 
controlled drug delivery carriers. 
 
Table 2 : Examples of peptide/protein controlled, release systems based on PLGA. 
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1.2. PLGA Micro and Nanoparticles 
 
The importance of the copolymers of PLA and PLGA is greatly increased in 
consequence of the possibility to prepare them from particle systems for the 
delivery of drugs. The advantages of use of particle systems include, in fact, 
the possibility of administering the medication directly to the site of action 
where the system forms a deposit from which the active ingredient can be 
released and act for a prolonged period of time. 
Within particles, two different categories can be distinguished: microparticles 
and nanoparticles. The distinction between both classes is often confusing 
and even polemic. Lately, the most accepted classification reports that 
particles up to 100 nm are considered nanoparticles while the ones from 1 μm 
up to 1,000 μm are classified as microparticles. 
Particulate systems as DDS can be prepared using different types of materials 
like polymers, lipids or peptides. Particles prepared from either natural or 
synthetic polymers have been extensively investigated to be applied as DDS. 
Their synthesis can be achieved from different techniques
14
. Among them, 
are emulsion polymerization, solvent evaporation, ionic gelation, self-
assembly, nanoprecipitation and supercritical fluid technology
15
.  
The release of the active principle to be based microspheres of biodegradable 
polymers is governed by the diffusion of the active principle through the 
polymer matrix and the biodegradation of the polymer matrix itself. 
The mechanism of the release of active molecules from PLGA microspheres 
is mainly governed by autocatalytic bulk degradation process-based. It was 
also shown that this mechanism is affected by many physical and chemical 
factors, such as the initial pH, ionic strength and temperature of the external 
environment, the ratio of the copolymers, the molecular weight, the 
crystallinity and the size of the species. 
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In the combined diffusive-erosive mechanism an important role is played in 
the environment of the activity of the water release. The particle, in contact 
with the aqueous environment, hydrates and water that gets inside solubilizes 
the drug, which begins to spread through the macroporous structure of the 
microspheres of PLGA (feature sizes: 10
-10
 - 10
-9
 nm ), whose existence and 
characteristics depend on the techniques of preparation of the microspheres 
(i.e., multiple emulsion technique). 
The release of macromolecules can be prevented by the microporosity of the 
system, since the size of the micropores can be comparable to those of the 
molecule to release. Following the degradation of the polymer micropores 
increase in size until it is allowed the transport of the macromolecule
16
.  
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1.3. Protein and Peptide in PLGA particles : Instability and 
Inactivation problems 
 
Many proteins and peptide are fragile molecules that undergo different 
pathways of instability and they have limited half-life  in vitro and in vivo 
and need to be carefully handled. The integrity of protein structures is 
essential for their proper function in physiological or pathological conditions. 
Unexpected unfolding or degradation of proteins may lead to inactive, 
sometimes even toxic products. Protein instability, generally, can be divided 
into two chemical and physical processes. Chemical instability involves the 
formation and destruction of covalent bonds, which usually occurs in the 
primary structure and disulfide bonds. Chemical process includes hydrolysis 
(proteolysis), deamination, racemization, oxidation, disulfide formation and 
β-elimination. The degradation products result from chemical instability must 
be carefully characterized for safe use of the proteins. Physical stability refers 
to proteins’ ability to retain their secondary, tertiary and quaternary structure, 
which can be lost by reversible or irreversible denaturation through a loss of 
tertiary structure, aggregation and adsorption. 
A major issue with PLGA delivery systems is protein stability during 
preparation, storage and release. There are several factors associated with this 
polymer that may cause destabilization of proteins. The potential inactivation 
mechanisms involved and stabilization approaches during protein 
encapsulation and release have been reviewed
17–20
. During microsphere 
preparation, proteins are exposed to conditions that are known to cause 
denaturing and aggregation, namely high shear, elevated temperature, 
exposure to the air/liquid interface, organic solvents and the oil in water 
(O/W) interface. Higher energy emulsification methods such as by 
sonication, homogenization and vortex are detrimental to proteins
21,22
. The 
addition of an aqueous protein solution to an organic solvent can lead to 
denaturing of proteins. Proteins, which are surface active, can diffuse to the 
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O/W interface and aggregate non-covalently or covalently upon exposure of 
the hydrophobic core and subsequent disulfide scrambling. A solid state 
protein is desirable when an organic solvent exposure is necessary and when 
the surface-association is the dominating mechanism for protein instability. 
The conformation of lyophilized protein is “trapped” when it is added to 
organic solvent, because the lack of lubricating water
23
. In addition, 
decreased mobility of proteins upon dehydration stabilizes them against shear 
and elevated temperature encountered during emulsification. 
During release from polymer microparticles, proteins are exposed to many 
stresses that can compromise the physical and chemical stability of proteins. 
These include protein rehydration, exposure to soluble oligomers, low pH, 
interactions between protein and polymer, loss of stabilizing excipients, and 
physiological temperature.  
Interactions between protein and polymer, such as adsorption can also affect 
the stability of proteins. Adsorption occurs by a hydrophobic interaction 
between the polymer and the hydrophobic interior of proteins and can often 
lead to the formation of insoluble aggregates or irreversible conformational 
changes
24
. Even when adsorption is reversible, it may accelerate other 
deleterious reactions by exposing previously buried residues or increasing 
side chain mobility. Adsorption can be minimized by the addition of other 
proteins or surfactants that compete with the protein for hydrophobic 
interactions with the polymer
25
. 
 
1.3.1. Stabilization strategies of Growth Factor in PLGA Delivery 
System 
 
Several stabilizers that have been proven to effectively improve protein 
stability in the polymer have been summarized in table 3. However, 
individual protein needs to be carefully studied for better selection of 
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stabilization strategies, but in general we can intervene on two fronts: during 
the phase of preparation and/or during the release phase. 
 
.  
Table 3 : Approaches to protect microencapsulated protein against stress factor during precipitation, 
storage and release 
During the preparation, the addiction of excipients, such as BSA 
26
, PEG400 
27
 and other, to the inner aqueous phase that compete with the water/organic 
solvent interface can prevent emulsification-induced denaturation and 
aggregation. This approach may be particularly useful when PLGA 
microparticles are loaded with low amounts of therapeutically potent 
proteins. On the other hand, increasing the protein concentration during 
emulsification was shown to result in higher absolute amounts of aggregated 
protein at the interface, indicating that multi-layer interfacial adsorption can 
occur 
28
.  
Common surfactants have not been very successful as stabilizer in the 
emulsification step because they seem to have an insufficient competition 
with the protein for the water/organic solvent interface, or promotion of 
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organic solvent/ protein contacts through hydrophobic contacts with both 
components.  
 
Another approach to protect proteins against degradation during 
emulsification has been pre-entrapment in a hydrophilic core, which is 
subsequently encapsulated in PLGA microparticles 
29
. Although this 
approach generally improved release characteristics, in none of these studies 
data on the protein structure were reported. 
During the release phase specific stabilization approaches to minimize 
protein degradation associated with the direct environment of (degrading) 
PLGA are often needed. To inhibit acid-induced protein degradation inside 
the microparticles during release (if occurring at all in vivo), co-incorporation 
of poorly water-soluble basic inorganic salts, such as magnesium hydroxide 
30
, calcium carbonate and sodium bicarbonate 
31
. 
Finally the addition of poloxamers, such as Pluronic F68, induces a decrease 
of the interactions of the macromolecule with the free carboxyl residues of 
PLGA and at the same time, it reduces the effects of the decrease in pH in the 
microenvironment of the particle, as evidenced by an increased release rate of 
protein 
32
.  
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2. Regenerative Medicine and the importance of Growth Factors 
release 
 
As a consequence of disease or trauma, the tissues and organs in our bodies 
may be unable to perform their anatomical and metabolic functions. Until 
recently the use of implants, and in severe cases transplants, is the only way 
to deal with these pathological conditions 
33
.  
In recent years, a new branch of regenerative medicine called tissue 
engineering is under development. This term, officially coined in 1988 by the 
National Science Foundation, indicates that this multidisciplinary field 
produces biological substitutes containing living and functional cells for 
regeneration, maintaining or improving performance of the tissue 
34
. Tissue 
engineering represents the meeting point of different disciplines such as 
medicine, biology, engineering, and chemistry with the common purpose for 
obtaining or replacing organs or parts of organs in the human body. This will 
make possible to have a viable alternative to transplantation, as this can have 
many fundamental problems such as the chronic shortage of donors, the 
phenomena of organ rejection and the continued need to take 
immunosuppressive drugs 
33
.  
Tissue engineering (TE) aims at the repairing and restoring damaged tissue 
function employing three fundamental “tools”, namely cells, scaffolds and 
growth factors (GFs) which, however, are not always simultaneously used 
35
 
36
. On the other hand, summoning recent experimental and clinical evidences 
indicate that the success of any TE approach mainly relies on the delicate and 
dynamic interplay among these three components and that functional tissue 
integration and regeneration depend upon their sapient integration 
37
. Future 
generation of scaffolds will have to provide not only the adequate mechanical 
and structural support but also have to actively guide and control cell 
attachment, migration, proliferation and differentiation. This may be 
achieved if the functions of scaffold are extended to supply biological signals 
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able to guide and direct cell function through a combination of matricellular 
cue exposition and GF sequestration and delivery 
37
. Therefore an ideal 
scaffold should possess a three-dimensional and well defined microstructure 
with an interconnected pore network, mechanical properties similar to those 
of natural tissues, be biocompatible and bio-resorbable at a controllable 
degradation and  resorption rate as well as provide the control over the 
sequestration and delivery of specific bioactive factors to enhance and guide 
the regeneration process.  
To overcome the problem of the in vivo instability of growth factors that are 
used to induce tissue regeneration, it is vital to use technology to develop the 
administration form. Indeed, when a solution of the growth factor is injected 
into the site requiring regeneration, the biological effect cannot be always 
predicted. This is because the growth factor is rapidly diffused away from the 
injection site. To enhance the in vivo efficacy of the growth factor, the drug 
delivery system (DDS) is promising. It is possible that when used in 
combination with an appropriate DDS technology, the growth factor 
enhances the in vivo proliferation and differentiation of key cells that 
promotes tissue regeneration. For example, the controlled release of a growth 
factor at the site of action over an extended time period is performed by 
incorporating the factor into an appropriate carrier. It is also possible that the 
growth factor is protected against proteolysis, as it is incorporated in the 
release carrier for prolonged retention of the activity in vivo. DDS 
technology can be also useful for half-life prolongation, absorption 
improvement and targeting, applicable in tissue engineering using protein and 
genes. 
 
2.1. ECM – Extra Cellular Matrix 
 
The extracellular matrix represents the secreted product of resident cells 
within each tissue and organ and is composed of a mixture of structural and 
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functional proteins arranged in a unique, tissue specific three-dimensional 
ultrastructure. These molecules, mainly proteins, provide the mechanical 
strength required for proper function of each tissue and serve as a conduit for 
information exchange (i.e. signaling) between adjacent cells and between 
cells and the ECM itself. The ECM is in a state of dynamic reciprocity 
38
 and 
will change in response to environmental cues such as hypoxia and 
mechanical loading.  
In addition to the direct regulation of cell function by ECM molecules, cell 
function is also dependent on the signaling of various growth factors and 
cytokines. Growth factors and cytokines are general terms for soluble 
molecules, in contrast to the typical solid-state for ECM molecules, which 
regulate functions such as proliferation, migration, differentiation and 
apoptosis. 
These molecules are secreted by cells, to act in an autocrine nature on the 
producing cells, or in a paracrine fashion on neighboring cells. Due to the 
central importance of these molecules in cell biology, they and their receptors 
and intracellular signal transduction pathways are major targets for 
manipulation in tissue engineering and regeneration strategies. Growth 
factors and cytokines interact with the ECM in a variety of ways, which 
allows one to potentially intervene in cell-growth factor interactions by 
modulating the ECM. The ECM can serve as a reservoir for many factors, 
due to their binding of the factors and protection from degradation. 
The ECM may also be involved in growth factor presentation to cells, and in 
regulating expression of the factors by cells. Specific examples of these 
interactions include the binding of growth factors such as FGF, vascular 
endothelial growth factor (VEGF), heparin-binding epidermal growth factor 
(HB-EGF), and HGF to heparan sulfate or heparin present in the ECM to 
form tight complexes. 
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2.2. Growth factor : Type and Mechanism of action 
 
Growth factors are soluble-secreted signalling polypeptides capable of 
instructing specific cellular responses in a biological environment. The 
specific cellular response trigged by growth factor signalling can result in a 
very wide range of cell actions, including cell survival, and control over 
migration, differentiation or proliferation of a specific subset of cells. 
The signal transmission mechanism initiates with the growth factor that is 
secreted by the producer cell which then goes to instructs cell behavior 
through binding to specific transmembrane receptors on the target cells 
(figure 3). The machinery that transduces the growth factor-binding signal to 
the cell nucleus involves a complex array of events involving cytoskeleton 
protein phosphorylation, ion fluxes, changes in metabolism, gene expression, 
protein synthesis and ultimately an integrated biological response 
39
.  
Growth factors differ from other oligo/polypeptide molecules, such as insulin 
and hormones, in the mode of delivery and response elicited. Typically, 
growth factors do not act in an endocrine fashion; they exhibit short-range 
diffusion through the extracellular matrix and act locally owing to their short 
half-lives and slow diffusion. The ability of a growth factor to deliver a 
particular message to a distinct subpopulation of cells is not exclusively 
determined by the identity of the growth factor and its ability to diffuse 
through the extracellular matrices (ECMs); it is also determined by the target 
cell number, type of receptors and the intracellular signal transduction 
subsequent to factor binding. The same growth factor can convey 
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Figure 3 : Cross talk between cells mediated by growth factors and ECM. The producer cell secretes 
soluble growth factors that bind to target cell receptors 
 
different instructions depending on the receptor type to which it binds, and on 
the cell type to which it binds. Moreover, the same receptor can translate 
different messages depending on the intracellular transduction pathways, 
which can differ from one cell type to another. The ultimate response of a 
target cell to a particular soluble growth factor can also be governed by 
external factors, including the ability of the factors to  bind to ECM, ECM 
degradation and growth factor concentration and cell target location 
40
. 
 
2.3. ECM – mimicking Scaffold 
 
A natural ECM or its derivatives may actually not be the ideal scaffold for 
tissue engineering applications because tissue engineering should be an 
accelerated regeneration process compared to the natural development 
program. Mature tissue matrix often does not possess the highly 
interconnected macro or micropore structures to allow for quick and uniform 
cell population throughout, which is essential for a tissue engineering/repair 
process. Therefore certain artificially designed scaffold features (such as 
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porosity, pore size, interconnected pores, etc.) are necessary for optimal 
tissue engineering applications (accelerated tissue regeneration). In addition, 
there are always concerns over the possible immune rejection and pathogen 
transmission when a natural ECM is used 
41
. 
Because of the impossibility of using natural ECM although the central role 
that it plays in morphogenesis  tissue, it is essential, during the design of a 
three-dimensional scaffold, re-create all of its features.   
In particular, to mimic the functional and microstructural characteristics of 
the ECM, a scaffold must present: high degree of porosity, high surface to 
volume ratio, high degree of pore interconnection, appropriate pore size 
42,43
 
and finally release in a controlled manner various active molecules, such as 
cytokines and growth factors 
44,45
.  
 
2.4. Strategies for presentation of growth factors 
 
There are several strategies which we can control the growth factors release 
from the scaffold but in any case some points should be considered : 
 
 the loading capacity corresponds to the amount of growth factor that can 
be mixed or grafted into the scaffold; 
 the distribution relates to the way the growth factor is dispersed, which 
will influence the release kinetics; 
 the binding affinity defines how tightly the growth factor binds the 
system; this must be sufficiently low to allow release, but high enough to 
prevent uncontrolled release; 
 the release kinetics: its control allows the appropriate dose of growth 
factor to reach the cells over a given period of time; 
 the long-term stability: the system should enable growth factors to 
maintain their structure and activity over a prolonged period of time; 
 30 
 
 the economical viability: such biomaterials must further be easy to 
manufacture and to handle, and be cost-competitive. 
 
Two distinct strategies for biomaterial presentation of growth factors in tissue 
engineering have been pursued:  
 
 Chemical immobilization of the growth factor into or onto the matrix 
 Physical encapsulation of growth factors in the delivery system.  
Chemical methods have been investigated, but often result in the denaturation 
and activity lowering of protein because the functional groups of protein are 
chemically modified by immobilization reaction. Therefore, physical 
methods are preferable for growth factor integrity. In fact, such a physical 
immobilization is often observed in growth factors existing in the body 
46
. 
Some growth factors are naturally stored in the body; they are stored 
ionically with the acidic polysaccharides of ECM (such as heparin sulfate and 
heparin) because most of them have a positively charged site on the 
molecular surface. It is recognized that, when needed, the complexed growth 
factor is water solubilized by the enzymes secreted from the surrounding 
cells released from the ECM complex during ECM degradation. This 
complexation also protects growth factors from their denaturation and 
general enzymatic degradation in vivo. 
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CHAPTER 1 
INDUCTION OF ANGIOGENESIS PROCESS IN 3D - 
SCAFFOLD FOR BONE REGENERATION 
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1. Introduction  
Currently, the repair of critical bone defects resulting from trauma, 
infections, tumors or congenital malformations is one of the most pressing 
problems in orthopedic field. Actually, autogenous bone grafting is still the 
most widely used practice for bone repair because leads a good 
osteoconduction and osteoinduction, in addition to the complete absence of 
immunogenic reactions after surgery
47
. However, autogenous bone grafts are 
associated with the morbidity of donors
48
, additional surgical procedures for 
harvest, and limitations in the quantity and available bone size.  
Bone tissue engineering can become a good and promising alternative to 
conventional methods leading to overcoming the problems related to donor 
site morbidity and size limitations.  However, while reconstruction of small 
to moderate sized bone defects using engineered bone tissues is technically 
feasible, and some of the currently developed concepts may represent 
alternatives to autologous bone grafts for certain clinical conditions, the 
reconstruction of large volume defects remains challenging. Increasing 
evidences have demonstrated that the key factor for the poor repair with 
tissue-engineered bone is poor vascularization
49
. Bone is a highly 
vascularized tissue that relies on the supply of essential nutrients and oxygen 
from blood vessels for maintaining skeletal integrity. The development of a 
microvasculature and microcirculation is critical for the homeostasis and 
regeneration of living bone, without which, the tissue would simply 
degenerate and die
50
.  
To achieve a good bone tissue regeneration is essential to have a three 
dimensional structure, called scaffold, with specific physical and mechanical 
properties, such as high porosity, high interconnected pore network, high 
biocompatibility but especially capable of releasing in a controlled way 
bioactive molecules such as proangiogenic factors (VEGF) . 
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The bioactivation of the scaffold can be obtained or through simple diffusion 
of bioactive molecules across the polymer matrix, or through electrostatic or 
covalent immobilization of the molecule on the surface, but both techniques, 
however, have inherent limitations
35
. In the case in which the GF is dispersed 
directly inside the matrix, the subsequent release of the macromolecule will 
follow a kinetics that depends on the nature of the polymer that constitutes 
the scaffold and that will be difficult to control and predict. On the other 
hand, the immobilization strategies should take into account the structure and 
the site of action of GF, in order to immobilize the macromolecule and 
without compromising its activity
35
. Moreover, in both strategies, the activity 
of the macromolecule can be seriously compromised during the process of 
manufacture of the scaffold, in addition to not be properly protected from 
enzymatic degradation when in contact with the biological microenvironment 
in vivo.  
In any case, the use of DDS is strategic for the control of the concentration of 
signal molecules within tridimensional scaffolds
51
. Among the DDS, the 
microparticles based on PLGA appear to be excellent candidates for the 
delivery of GF in scaffolds for tissue engineering applications
52
. The 
microparticles made of PLGA can, in fact, protect the encapsulated molecule 
and release it at specific time intervals and for long periods of time during the 
development of the tissue. Furthermore, the possible micropositioning 
oriented in space of the particles inside the scaffold can make possible the 
control of tissue growth both in the extension and in the organization. 
 
1.1. Vascularization in early bone development 
Bone formation and development occurs through two distinct processes: 
intramembraneous and endochondral ossification and the vascularization is 
the prerequisite for both the processes
53
. In intramembranous bone formation, 
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mesenchymal stem cells (MSCs) can be transported through capillaries and 
differentiate directly into mature osteoblasts.  
These osteoblasts then deposit bone matrix and lead to bone formation. On 
the other hand, during the endochondral ossification, the chondrocytes secret 
angiogenic growth factors promoting the invasion of blood vessels, which 
then bring along a number of highly specialized cells and replace the 
cartilage mold with bone and bone marrow
54
.  
Vasculature also plays a key role in bone formation by the production of 
growth factors that control the recruitment, proliferation, differentiation and 
function of various cells including osteoblasts and osteoclasts
55
. During the 
bone remodeling, the osteoblasts play an important role in the balance of  
 
Figure 4 : A schematic diagram of endochondral bone formation. (A) Mesenchymal cells condense 
and (B) differentiate into chondrocytes forming an avascular cartilage model of the future bone. (C) 
At the centre of condensation the chondrocytes cease proliferating and become hypertrophic. (D) 
Perichondral cells adjacent to the hypertrophic chondrocytes differentiate into osteoblasts forming a 
bone collar. The hypertrophic cartilage regulates the formation of mineralised matrix; the release of 
angiogenic factors to attract blood vessels and undergoes apoptosis. (E) The coordination of 
osteoblasts and vascular invasion form the primary spongiosa. The chondrocytes continue to 
proliferate with concomitant vascularisation resulting in a coordinated process that lengthens the 
bone. Osteoblasts of the bone collar will eventually form cortical bone; while osteoblasts precursors 
located in the primary spongiosa will eventually form trabecular bone. (F) At the ends of the bone, 
secondary ossification centres develop through cycles of chondrocyte hypertrophy, vascular invasion 
and osteoblast activity. Columns of proliferating chondrocytes form in the growth plate beneath the 
secondary ossification centre. Finally, expansion of stromal cells and hematopoietic marrow starts to 
take place in the marrow space
56,57
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resorption and bone deposition by secreting osteoprotegerin that is an 
inhibitor of osteoclast activity. However, the mature osteocytes lose the 
capability to produce this molecule
58
. Blood vessels transport osteoprogenitor 
cells for the deposition of new bones
59
. The invading vasculature, thus, serves 
as both a reservoir and a conduit for the recruitment of essential cells 
involved in bone remodeling, and provides critical signals necessary for bone 
morphogenesis
60
. 
It follows that the balance between cartilage formation and vascular invasion 
is of fundamental importance during bone development and any change in 
this balance leads to growth plate thickening and a reduction in bone 
formation
61
. 
1.2. The role of VEGF in bone Regeneration  
Among all the growth factors that come into play during the processes of 
development, remodeling and repair of bone tissue, VEGF plays a crucial 
role in the phase of vascularization.  
From a structural point of view, the VEGF is a 46-kDa glycoprotein  that 
comprises six related proteins: VEGF-A, VEGF-B, VEGF-C, VEGF-D, 
VEGF-E and placenta growth factor. The most studied member of the VEGF 
family is VEGF-A. this family exist in different isoforms derived from the 
same gene by alternative splicing of messenger RNA and defined on the basis 
of the length of the amino acid chain, such as VEGF121, VEGF165, 
VEGF189, VEGF209 in humans
62
. 
VEGF plays several effects during the bone regeneration both directly and 
indirectly on osteoblast differentiation improving the bone formation. The 
vegf, in fact, acts directly on osteoblasts by promoting the osteoblast 
migration, proliferation and differentiation, and also playing a mediating role 
of different osteoinductive factors, such as TGF, IGF-I e FGF-2, which 
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upregulate VEGF expression in osteoblasts
63–65
. VEGF also acts on 
osteoblasts also indirectly by stimulating the endothelial cells on the one 
hand and on the other to produce anabolic factors that improve the bone 
formation.  
Treatment with an anti-VEGF chimeric protein was found to inhibit blood 
vessel formation during endochondral ossification and led to compromised 
bone formation
66
. VEGF may be considered the major factor coupling 
between osteogenesis and angiogenesis
66
. 
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2. 3D – Scaffold for bone regeneration 
In order to regenerate the natural tissue you have to make three-dimensional 
structures that  induce tissue regrowth with specific stimuli. Recent studies 
show that the isolated cells are hardly capable of organize themselves 
spontaneously to form complex tissues in the absence of three-dimensional 
structures able to guide and stimulate their activity
67
. In most cases, the 
cultured cells examined tend to multiply and proliferate only in two 
dimensions The three-dimensional tissue regeneration requires, therefore, a 
support (scaffold) that emulates the extracellular matrix for the organization 
of cells in complex structures. The role of the scaffold is to induce tissue 
regeneration by providing a "temporary guide" for cell growth, under 
appropriate culture conditions, to facilitate the process of differentiation
68
. 
These structures must show, under ideal conditions, good qualities of 
mechanical stability, preserving the specific characteristics of biological 
compatibility. Consequently, during the design phase must consider two 
distinct sets of parameters: the biological parameters, related to the 
interaction with the cells which it comes in contact, and engineering 
parameters, related to the mechanical and microstructural features of the 
system. In particular, the main parameters that must be considered are: 
 
 Biocompatibility One of the primary requirements of any bone scaffolds 
is biocompatibility linked to the need to improve and / or restore a 
specific biological function, without interfering or interact in a harmful 
way with the physiological activities of the organism. An ideal bone 
scaffold must be osteoconductive where the scaffold allows the bone cells 
to adhere, proliferate, and form extracellular matrix on its surface and 
pores. The scaffold should also be able to induce new bone formation 
through bio-molecular signaling and recruiting progenitor cells, a 
property known as osteoinduction. Furthermore, an ideal scaffold needs to 
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form blood vessels in or around the implant within few weeks of 
implantation to actively support nutrient, oxygen, and waste transport
69
. 
 
 Mechanical properties The mechanical properties of an ideal bone 
scaffold should match host bone properties and proper load transfer is 
important as well. Mechanical properties of bone vary widely from 
cancellous to cortical bone. Young’s modulus of cortical bone is between 
15 and 20 GPa and that of cancellous bone is between 0.1 and 2 GPa. 
Compressive strength varies between 100 and 200 Mpa for cortical bone, 
and between 2 and 20 MPa for cancellous bone. The large variation in 
mechanical property and geometry makes it difficult to design an ‘ideal 
bone scaffold’69. 
 
 Pore size A must have property for scaffolds is interconnected porosity 
where the pore size should be at least 100 mm in diameter for successful 
diffusion of essential nutrients and oxygen for cell survivability. 
However, pore sizes in the range of 200–350 mm are found to be 
optimum for bone tissue in-growth. Furthermore, recent studies have 
indicated that multi-scale porous scaffolds involving both micro and 
macro porosities can perform better than only macro porous scaffolds. 
Unfortunately, porosity reduces mechanical properties such as 
compressive strength, and increases the complexity for reproducible 
scaffold manufacturing.  
 
 Bioresorbability Bioresorbability is another crucial factor for scaffolds in 
bone tissue regeneration. An ideal scaffold should not only have similar 
mechanical properties that of the host tissue, but also be able to degrade 
with time in vivo, preferably at a controlled resorption rate and eventually 
creating space for the new bone tissue to grow. The degradation behavior 
of the scaffolds should vary based on applications such as 9 months or 
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more for scaffolds in spinal fusion or 3–6 months for scaffolds in cranio-
maxillofacial applications. Naturally, design and manufacturing of multi-
scale porous scaffolds having ideal composition including targeted 
biomolecules, mechanical properties and related bioresorbability are some 
of the key challenges today towards their successful implementation in 
bone tissue engineering. 
 
2.1. Bottom-up approach for tridimensional scaffold realization 
Based on the engineering and biological parameters listed above, one of the 
main objectives to be achieved during the design of scaffolds is to guarantee 
accurate control over their macroscopic properties (e.g., geometry, 
mechanical strength, density, porosity) and microstructural (e.g., size, 
interconnection of the pores) and on their bioactivation (surface 
functionalization, release of growth factors). 
For this purpose there are several techniques that depend on the type of 
polymer used and the application intended. In recent years, many studies in 
the literature have focused on the development of porous scaffolds by 
sintering of ceramic or polymeric microparticles, in order to overcome 
several limitations that are found in conventional techniques, mainly related 
to the mechanical properties, pore interconnection, as well as the use of toxic 
solvents. For this reason, in this project we propose a bottom up approach 
founded on the assembly of building blocks by solvent induced microparticle 
sintering to realize multifunctional polymer scaffolds with predefined pore 
dimension and fully percolative pathway, able to include interspersing 
microdepot for the release of bioactive molecules. This approach offers the 
possibility to realize scaffolds that not only meet all the requirements in terms 
of controlled microstructure, chemical stability and mechanical response 
necessary to support neo-tissue growth, but also provide a guidance of cell 
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and tissue processes by presenting bioactive agents in a predefined chrono-
programmed manner. 
This technique of sintering polymeric microspheres is based on partial 
dissolution of the microsphere surface, based on Flory–Huggins solution 
theory, to form porous three dimensional structures for tissue engineering 
applications. 
Flory–Huggins solution theory deals with the interplay between 
monomer:monomer and monomer: solvent interaction in a polymer:solvent 
mixture. By a specific solvent/non-solvent mixture is possible to stabilize a 
balance between polymer dissolution and precipitation. During this 
intermediate state the microsphere surfaces were susceptible to bonding with 
adjacent microspheres prior to precipitation of the intertwined surface chains 
and sintering of the microspheres. 
The use of specific solvent/non-solvent mixture  under mild temperature 
during the sintering polymeric microspheres overcome some limitations 
when treating with thermolabile bioactive molecules, such as growth factors, 
which tend to denature with temperature. 
The concept of sintering of microparticles originates from the process of 
densification of powders, at the base of the methods of production of ceramic 
materials, and is based on the fact that the system is able to redistribute their 
mass as a result of the formation of gradients of matter towards areas with 
high concentration of crystalline defects, triggered by appropriate conditions 
of temperature, leading to a densification of the system.  
The simplest case of a single phase sintering takes place when an aggregate 
of particles is heated. Must be analyzed two simple conditions: an initial state 
represented by two particles in contact and a final situation in which the 
pores are closed in a continuous matrix. The shrinkage, densification and 
elimination of the pores occurs at a rate determined by the initial size of the 
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particle, from the value of surface energy and viscosity of the material. To 
obtain porous materials the sintering must be stopped at the first stage, by 
choosing appropriate parameters. 
When the spheres begin to coalesce, the adhesion from spheres has a radius 
of curvature smaller than the curvature of the particle surface, leading to a 
negative pressure which causes a viscous flow of the material along the inter-
particle region (Fig. 5)
70
. 
 
Figure 5 : schematization of a junction point formed between two beads in contact 
 
There are a number of different pathways for the transport of material 
towards the area of the junction point during the initial stage. Some of these 
lead to densification, which consists in the process of narrowing that 
determines the approach of the centers of the microparticles. The other 
transport mechanisms lead to coarsening, which consists in the growth of the 
junction between the particles, resulting in a reduction of the specific surface 
area without any shrinkage. Two possible routes for the transport of matter 
take place by evaporation/condensation or by surface diffusion. These 
mechanisms of coarsening determine the displacement of material from the 
surface of the particles to the junction points, leading to a reduction of 
surface energy
70
. 
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The transport mechanism that determines the speed of growth of the junction 
points greater will be the dominant mechanism and cause coarsening or 
densification. The particle size is very important in determining the speed, in 
that, in the equation of sintering there is a dependence from the inverse 
particle radius r. At constant temperature and composition of the equation of 
the speed for the densification and coarsening is: 
(
 
 
)
 
 
 
  
  
where, k is a constant that contains the surface tension and the diffusion 
coefficient, n varies between 2 and 6 and between 2 and 4
70
. 
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3. Materials and Methods 
 
3.1. Materials 
 
The acid poly (D, L-lactic-co-glycolic acid) (PLGA) 50:50 (Resomer ® RG 
504H, i.v. 0:32 to 0:44 dl/g) was purchased from Evonik® (Germany). The 
poloxamer188 (Pluronic
 ®
 F68, Mw 8400, HLB 29), the polycaptolactone, 
the polyvinyl alcohol (Mowiol 40-88) bovine serum albumin (BSA), heparin 
sodium salt (Hp), the substrate liquid ABTS (2,2 '-azino-bis (3 - 
etilbenzotiazolin-6-sulfuric) acid) and phosphate buffer (0.01M Na2HPO4, 
0.0027 M KCl and 0.137 M NaCl, pH 7.4) were purchased from Sigma 
Aldrich (USA). The VEGF growth factor with the respective ELISA kit for 
the quantitative determination were provided by Peprotech (New Jersey, 
USA). All solvents used are of analytical grade and HPLC grade and were 
supplied by Sigma Aldrich (USA). The water used was filtered through 0.22 
μM filter (Millipore, USA).  
 
3.2. Microparticles Preparation 
 
3.2.1. Polycaprolactone Microparticles 
 
The PCL microparticles were prepared by the technique of oil in water 
(O∕W) single emulsion with solvent evaporation. Briefly, a polymer solution, 
obtained by dissolving the polycaprolactone in dichloromethane (20 ml, 10% 
w∕v), is added dropwise into 400ml of a aqueous PVA solution ( Mowiol ® 
40-88 ) with 0.1% of Tween 21. The presence of such emulsifying agents in 
the aqueous phase is essential for reducing the phenomena of coalescence 
and aggregation of the microspheres during the evaporation of the solvent. 
The two solutions are mixed for three hours at a suitable speed, using an 
electronic stirrer (RZR 2102, Heidolph, Germany), so as to allow the 
complete evaporation of volatile organic solvent and  in order to obtain the 
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dispersed microparticles. After, this microparticles are filtered and washed 
three times with distilled water to remove the emulsifying agents, and finally 
allowed to dry under a chemical hood. 
 
3.2.2. PLGA microparticles for controlled release of VEGF 
  
The microspheres of PLGA containing VEGF were prepared by the 
technique of multiple emulsion/solvent evaporation (W/O/W) with growth 
factor theoretical loading of 0.01% (0.01 mg to 100 mg of VEGF 
microparticles). VEGF has been encapsulated in combination with stabilizing 
agents: the bovine serum albumin (BSA) and heparin sodium salt ( Hp). A 
sterile solution in PBS, pH 7.4, containing VEGF, Hp and BSA ( ratio VEGF 
/ Hp / BSA 1:1:70 w / w / w) (250 μl) , was emulsified by homogenization at 
8000 rpm for 1 minutes ( Ultraturrax T25 Basic, probe 8G, IKA, Germany ), 
in 10 ml of a solution of PLGA and poloxamer 188 (5:1 ratio) in 
dichloromethane (10% w/v) . 
The emulsion thus obtained was added  to the external phase consisting of 40 
ml of an aqueous PVA solution (0.5% w/v) (Mowiol® 40-88), and emulsified 
by an electronic stirrer (RZR 2102, Heidolph, Germany),  at 400 rpm for 3 
hours, at room temperature, in order to facilitate the evaporation of the 
organic solvent and the precipitation of the polymer in the form of 
microparticles. Thereafter, the microparticles were isolated and washed with 
30 ml of distilled water 3 times, by centrifugation at 5000 rpm for 10 minutes 
at 4⁰C, and subsequently subjected to a lyophilization cycle of 24 hours 
(0,001 atm , -60°C ) (Freeze Dryer Alpha 1-4 LD plus, Martin Christ, DE). 
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3.3. Dimensional and Morphological analysis of microparticles 
 
a) Scanning electron microscopy observation 
The morphology and the internal structure of the microspheres was visualized 
using scanning electron microscopy (SEM) (Zeiss, FEG Ultraplus, 
Germany). A small quantity of plain microspheres was sprinkled on the SEM 
stubs and coated using a SEM coating system (Cressingthon, 208 HR, UK) 
with 10nm of platinum-palladium under an argon atmosphere. Samples were 
then observed for their surface morphology by SEM and photographs were 
taken at 20000 Kv and different magnification. One stub was made for each 
batch and many pictures were taken of each stub.  
b) Particle size analysis 
The average diameter and the particle size distribution was determined using 
a laser granulometer (Mastersizer 2000, Malvern Instrument, UK) from 
previously lyophilized microspheres suspended in an aqueous solution of 
PVA 0.5% (w/v). For each formulation the average diameter of the particles 
was expressed in microns ± standard deviation (SD) of the measurement 
carried out on three different batches of microspheres. 
 
3.3.1. VEGF Encapsulation efficiency and Quantitative analysis 
 
VEGF encapsulated and released from the microspheres was quantified by 
specific immunoenzymatic assay ELISA (Enzyme-linked immunosorbent 
assay), according to the procedure recommended by the manufacturer 
(ELISA Kit
®
, R&D Systems, USA). The standard solution of VEGF or the 
sample to be analyzed to appropriately diluted unknown concentration (200 
uL) and 50 μ l of dilution buffer provided by the manufacturer (RD1W) were 
added to each well of the multiwell plate coated with a specific monoclonal 
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antibody of VEGF. The loaded plate was incubated for 3 hours at room 
temperature and then washed 3 times with a washing solution (Wash Buffer). 
Following the wash, we proceed with the addition of VEGF specific 
polyclonal antibody conjugated  to the enzyme peroxidase. The plate is 
maintained in incubation at room temperature for 2 hours and then, after 
three washes, to each well to be analyzed is adds the substrate solution 
composed of hydrogen peroxide and chromium-tetramethylbenzidine (ratio 
1:1). After 20 minutes of incubation at room temperature and subsequent 
washing, the colorimetric reaction is stopped with 50 μl of a solution of 
sulfuric acid 2 N. The optical absorbance was measured by 
spectrophotometer to the wavelength λ = 450nm. 
 
 Encapsulation efficiency of microparticles 
The amount of VEGF encapsulated within the microspheres was determined 
by degradation of the polymer matrix by basic hydrolysis, in a solution of 
sodium hydroxide. One mg of microspheres was suspended in 1 ml of 0.1 N 
NaOH and maintained at room temperature for about 24 hours. The obtained 
solutions were centrifuged at 4500 rpm for 15 minutes at 4°C, and the 
supernatant analyzed for the content of VEGF by ELISA, as previously 
described. The results were expressed as percentage encapsulation real or 
actual loading (mg VEGF encapsulate for  mg of microspheres) and 
encapsulation efficiency (mg encapsulated real VEGF / VEGF theoretical X 
100 mg) ± standard deviation (SD) of the measurement carried out on three 
different batches. 
 
 In vitro Release kinetics  
In vitro release studies of VEGF were made by suspending 5 mg of 
lyophilized microparticles in 1 ml of PBS pH 7.4, previously filtered through 
filter pores of 0.22 μm in diameter (Millex®, Millipore, USA). The samples 
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were incubated in a incubator at 37 ° C and 30 RPM, to mimic the conditions 
of release of the microspheres dispersed in a scaffold.  
At regular intervals of time, the samples were centrifuged at 300 rpm for 5 
minutes at 4 ° C and the release media removed and replaced with the same 
volume of fresh PBS pH 7.4. The samples taken were analyzed by ELISA, as 
described previously, to determine the amount of growth factor released. The 
results were expressed as ng of VEGF released per mg of microparticles ± 
standard deviation (SD) of the measurement carried out on three different 
batches. 
 
3.3.2. VEGF released bioactivity 
 
The HUVEC cells were previously prepared and characterized in Human 
Endothelial-SFM Basal Growth Medium in the presence of HI-FBS, EGF 
(100 μg/ml), Hp (100 μg/ml), sodium penicillin and sulfate streptomicin 
(respectively 10.000 U/mL penicillin e 10.000 μg/mL of streptomicin).  
For the assay of VEGF proangiogenic activity on Matrigel has been used a 
plate with 24 wells. For each well have been added 230 μl of Matrigel (13 
mg/ml) (R&D Systems), the plate was been incubate for 30 minutes at 37°C 
in order to obtain the formation of a gel. Subsequently, the HUVEC cells 
were stratified on this gel at a concentration of 8x10
4
 cells\ml of serum-free 
medium, in presence of VEGF microspheres (mg of microspheres 
corresponding to 20 ng/ml di VEGF released) or in presence of free growth 
factor (20 ng/ml). 
The cells were incubate at 37°C to promote adherence to the gel layer. After 
6 hours of incubation, is possible observe, at inverse microscopy, the 
formation of capillary network. Finally the cells were fixed with PBS 
containing glutaraldehyde at 0,2% (v/v) paraformaldehyde at 1% (w/v), 
photographed and analyzed by a specific software (Scion Image). 
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3.4. 3D – Scaffold 
 
3.4.1. Scaffold Preparation: Microparticles Solvent Sintering 
Once optimized the process of the microparticles fabrication was proceeded 
to their compaction using a random packing of such particles, in order to 
obtain a three-dimensional porous structure. Approximately 75 mg of PCL 
microparticles, previously sieved to obtain a suitable size range, are placed in 
a teflon mold with a diameter of 10 mm and height of 2 mm. Subsequently a 
solution of solvent/non solvent (30/70 v/v) are cast on the particles spreading 
by capillarity within the interstices formed between the microparticles. This 
solution was left to evaporate from the molded microspheres for 30 minutes 
under a chemical hood before and being placed under vacuum for an 
additional 24 hours in order to allow the complete evaporation of the 
solvent/non-solvent sintering solution (Fig.6).  
For the achievement of the bioactive scaffolds, 5mg of PCL microparticles 
are replaced with the same mg of microspheres containing VEGF. 
 
 
Figure 6 : schematization of the process of scaffolds realization 
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The different types of scaffolds are summarized in Table 4: 
Type Dimensional range (µm) 
scaffold Protein-free 200-300 
scaffold Protein-free 300-355 
scaffold Protein-free 355-425 
scaffold Protein-free 200-425 
Bioactive scaffold 200-300 
Bioactive scaffold 200-425 
Table 4 : different types of scaffolds realized by solvent sintering 
 
3.4.2. Surface Treatment 
The surface hydrophobicity is well known as one of the key factors to govern 
cell response. More studies were showed that more  hydrophilic is the surface 
of material films much more is  the cell adhesion on the surface, for example, 
osteoblast adhesion was reported decrease when the contact angle of surface 
increased from 0° to 106°
71,72
. Moreover the preferential adsorption of some 
serum proteins (like fibronectin and vitronectin in culture medium and/or 
from cell secretion) onto the hydrophilic surfaces containing hydroxyl and 
carboxylic acid groups may be the reason for the better cell adhesion, 
spreading, and proliferation
73,74
. For this reason, we have modified the 
surface of the scaffold  by two different treatments : 
a) hydrolysis of the surface witch Ethanol\0.5N NaOH mix solution 
(15min, 200 RPM)  to increase the percentages of hydroxyl (–OH) and 
carboxylic acid (–COOH) groups on the surface area. 
b) O2  plasma treatment. The plasma treatment was carried out on a  
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Gmbh Plasma Deposition System (Model Femto Diener, 13.53 Mhz, DE) 
under O2 at 20%. The chamber was evacuated to less than 10 Pa before filling 
with oxygen. After the pressure of the chamber had stabilized to a proper 
value, glow discharge plasma was created by controlling the electrical power 
at a radio frequency of 13.56 MHz for a predetermined time (3min). 
Static contact angle measurements were used to study the effect of different 
treatments on the surface of bioactive scaffolds, fabricated by solvent 
sintering. The surface wetting characteristics were examined with a drop-
shape analysis system. Deionized water droplets (~ 4 µL) were delivered to 
the sample surface by a syringe at room temperature and the droplet 
configuration was captured with a camera. From the measured angle between 
the droplet baseline and the tangent at the water/air boundary, a contact angle 
was calculated as the average of the measured left and right contact angles. 
For statistical analysis, six contact angle measurements were obtained from 
three different surface regions of two identical samples. 
3.4.3. Morphological characterization 
 
a. Scanning electron microscopy observation 
 
The SEM analysis of the sintered scaffolds was carried out to study the 
morphology and qualitatively evaluate the extension of the junctions between 
the microparticles and the porosity in terms of distribution, pore size and 
degree of interconnection. Briefly a section of scaffold was sprinkled on the 
SEM stubs and coated using a SEM coating system (Cressingthon, 208 HR, 
UK) with 15nm of platinum-palladium under an argon atmosphere. One stub 
was made for each type of scaffold and seven pictures were taken of each 
stub at different magnification. 
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b. Atomic Force Microscopy observation  
 
The atomic force microscope is a member of the scanning probe microscopy 
techniques that utilize a probing tip that scans the surface of a sample. The 
measured interaction between the sample and the probe (e.g. current in 
scanning tunneling microscopy or force in AFM) renders a three-dimensional 
image of the sample surface
75
. 
This microscope was used to study the surface morphology of treated and 
untreated scaffold. The samples were analyzed with a Nanowizard II 
microscope (JPK, Santa Barbara, CA). AFM images were recorded in contact 
method at room temperature in air using silicon cantilevers. Height phase 
images were recorded with the maximum available number of pixels 
(512×512). Three-dimensional images were acquired using Nanowizard 
image processing software. The roughness were carried out using the cross 
section analysis.. 
 
3.4.4. Micro – CT characterization 
A precise and quantitative analysis of porosity  of the sintered scaffolds, in 
terms of distribution, pore size and degree of interconnection has been 
obtained by microcomputed tomography (micro-CT), a radiographic method 
for the production of cross sectional images of bodies. 
The information originates from the X-ray attenuation measurement that 
undergo crossing the sample. The result of this process is the formation of 
two-dimensional image (projection). Now if the sample or the detection 
system are rotated, you will get many projections how many are the angles of 
rotation. The composition of these projections (using sophisticated 
algorithms) provides an image of a slice of the sample. If you rotate one of 
the components of the system, you add a translation motion of the system X-
ray source-sample-detector you can get the individual slices at different 
 52 
 
heights; overlaying this slices it is possible to obtain a reconstruction of the 
entire volume of the sample and then the full view of its internal structures
76
.  
Three samples for each type of sintered scaffolds was subjected to 
topographical analysis and through the images of the section collected, 
implemented through dedicated software (CTAn) it was possible to calculate 
several characteristic parameters (total porosity, average pore size and pore 
distribution) based on the size of the individual pixels that defines the image 
resolution. 
 
3.4.5. Mechanical characterization 
 
To evaluate the mechanical properties of the sintered scaffolds was 
performed a test of static compression through the use of a dynamometer 
(Istron, Model 5942) in order to determine the strength, the elastic modulus 
and deformation for each type of sample. The compression tests were 
performed, in reference to ASTM 695/2°, on samples of cylindrical geometry 
with a diameter of 10 mm and a height of 2 mm. It is used a preload of 0.5N 
and e load cell of 1N, setting a speed of the moving crosshead of 1 mm/min. 
 
3.4.6. PCL/PLGA microparticles distribution study 
 
To evaluate the distribution of the PLGA microspheres, containing the 
growth factor, inside the scaffold, we are performed confocal microscopy 
analysis. Specifically, were made PLGA microspheres with the same 
procedure as above, but substituting the poloxamer 188 with one labeled with 
Rhodamine B. Subsequently this microspheres have been used for the 
preparation of several scaffolds (n = 10) and observed at confocal 
microscopy (λ = 485). The images obtained were analyzed and the 
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distribution of the marked microspheres in the volume of the scaffolds was 
calculated. 
 
3.4.7. Cells adhesion test on scaffold surface treated 
To evaluate the influence of the two treatments on the process of cell 
adhesion were carried out specific tests. The different types of scaffolds 
(untreated, plasma and EtOH/NaOH treated) are placed in 24multiwell plate 
and plated with human umbilical endothelial vein cells (HUVECs) suspended 
in  medium in order to obtain a surface concentration of 5 • 104 cells/cm2 . It 
is explicitly noted that is not added in the culture medium serum, which 
contains several adhesion proteins and growth factors that may adversely 
affect the adhesion test. In this way, then, you are sure that any cell adhesion 
is due solely to the contribution of the type of treatment. 
The different scaffolds are, at this point, placed in an incubator at 37 °C with 
a controlled atmosphere at 5% CO2. After 6h of incubation is carried out cell 
counts adhere to different scaffolds, through the Bürker chamber. In reality, 
this detection is the result of a cross-check between the number of cells that 
are located on the bottom of the container and in suspension, that, by the 
difference of the number of total cells plated, giving those who actually have 
adhered to the scaffolds. 
To observe cell morphologies, a part of the scaffolds seeded with cells, to 6h 
from the seeding, were fixed in 2.5% glutaraldehyde (SIC, Rome, Italy) in 
0.1 M sodium cacodylate (SIC), pH 7.3, washed three times for 10 min in the 
same buffer, post-fixed in 1% osmium tetroxide (SIC) in 0.1 M sodium 
cacodylate, pH 7.3, on ice for 1 hour, washed three times for 10 min in the 
same buffer  and dehydrated in ascending series of ethanol  on ice. At the end 
of dehydration, samples were put in critical point drying  (CPD Leica,) 
placed on aluminum stub  with carbon tape, coated with 20 nm of gold metal 
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by sputter coater (208 HR sputter coater cressington) and observed at a Zeiss 
ultraplus scanning electron microscopy. 
To observe cell proliferation, a part of the scaffolds seeded with cells, to 6h 
from the seeding, were fixed in 4% paraformaldehyde and subsequently 
labeled with phalloidin tetramethylrhodamine B isothiocyanate and Sytox 
green(Invitrogen) in accordance with the procedures recommended by the 
manufacturers. The samples were observed under a confocal 
microscope(Leica, model TCS SP5 II). 
 
3.4.8. Bioactive scaffold “In Vitro” Release kinetics  
 
In vitro release studies of VEGF from sintered scaffolds were made by 
suspending one scaffold in 1 ml of PBS pH 7.4, previously filtered through 
filter pores of 0.22 μm in diameter (Millex®, Millipore, USA). The samples 
were incubated in an incubator at 37 ° C and 30 RPM, to mimic the in vivo 
conditions. At regular intervals of time, the release media removed and 
replaced with the same volume of fresh PBS pH 7.4. The samples taken were 
analyzed by ELISA, as described previously, to determine the amount of 
growth factor released. The results were expressed as ng of VEGF released 
per scaffold ± standard deviation (SD) of the measurement carried out on 
three different batches. 
 
3.4.9. Cells – Bioactive Scaffold Interaction analysis 
The human endothelial cells (HUVECs) were used for the experiments of 
cell-material interaction. Approximately two hundred thousand cells were 
suspended in 200μl of culture medium containing 20% fetal bovine serum 
(FBS), a vascular endothelial growth factor (lg / mL), 1% pen/strep (10,000 
U / mL penicillin and 10,000 lg / mL streptomycin). The HUVECs were 
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seeded in a static way on bioactive scaffolds with PLGA microspheres 
containing VEGF. As a control, we used the same PCL scaffolds containing 
empty PLGA microspheres.  
After about two hours, time necessary to allow the cells to adhere to the 
material, was added to the above scaffold a complete medium containing 5% 
fetal bovine serum (in this time in order to assess the proliferative effect due 
to the only VEGF released from the microspheres). The samples kept in 
incubator for cells in static conditions after 1 and 7 days of culture were 
blocked in formalin for 20 min at room temperature. She was later performed 
a staining of actin microfilaments with phalloidin tetramethylrhodamine B 
isothiocyanate and of cell nuclei with Sytox green (Invitrogen) in accordance 
with the procedures recommended by the manufacturers. The samples were 
observed under a confocal microscope(Leica, TCS SP5 II). 
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4. Results and Discussion 
 
4.1. Microparticles characterization 
 
The morphology of all types of microspheres produced was evaluated by 
SEM. Are shown the micrographs relating to PCL and PLGA microspheres, 
in particular, for each type are shown two micrographs at different 
magnification, in order to emphasize the size distribution and surface 
morphology of the individual microspheres. 
 
Figure 7 : micrographs of Polycaprolactone microparticles at different magnification 
 
  
Figure 8 : micrographs of PLGA micropheres at different magnification 
 
From the micrographs shown (Fig. 7) it is found that the Polycaprolactone 
microparticles are spherical and non-porous. These properties are suitable for 
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the production of scaffolds for sintering, because microspheres of regular 
shape facilitate the formation of porous structures interconnected, while the 
surface porosity is not a necessary condition. Moreover, it is observed, a 
rather broad size distribution that does not allow an accurate control of the 
properties of the scaffold, because the presence of microparticles with wide 
dimensional range may involve an occlusion of the pores. 
From the micrographs shown (Fig. 8) it is found that the PLGA microspheres 
are spherical and porous. These characteristics are suitable to obtain a 
controlled and prolonged release of the dispersed growth factor. In fact the 
presence of a dense pore networks, which goes from the inside to the surface 
of the microspheres, as shown by the sections analyzed (Fig. 9), allows to 
control the release of the factor in the desired mode. 
 
           
Figure 9 : micrographs of sections of PLGA micropheres at different magnification 
 
4.1.1. VEGF encapsulation efficiency and “In Vitro” release kinetics 
 
The microparticles based on PLGA containing VEGF were prepared by the 
technique of multiple emulsion/solvent evaporation (W/O/A), widely used 
for the microencapsulation of proteins and growth factors.  
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The specific formulation conditions adopted have allowed to obtain 
microparticles able to encapsulate VEGF with an efficiency of encapsulation 
of about 55% (55.14% ± 2.16 ng VEGF for mg of microspheres).  
The release profile of VEGF by microparticles is shown in Figure X and is 
expressed as ng of VEGF released in active form for 1 mg of microspheres as 
a function of time. 
 
 
Figure 10 : Release profile of VEGF by PLGA microparticles (ng\mg of MS) 
 
As can be seen from the graph, the microparticles show an initial release of 
VEGF, in the first day of incubation, rather slow (<5 ng/mg), followed by a 
controlled release of VEGF sustained for over a month. In particular, the 
particles are able to provide constant release of VEGF of about 0.5 ng/mg 
daily for all period evaluated. 
These results suggest that the microparticles manufactured have excellent 
potential, when placed in three-dimensional substrates, promoting the 
activation of angiogenic processes, through careful control of the 
concentrations of GFs inside the scaffold. 
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4.1.2.  VEGF released bioactivity 
 
One of the basic requirements of a controlled release system of growth factor 
is to safeguard the maintenance of bioactivity during the encapsulation 
process. In this case the bioactivity of VEGF released from microparticles 
was evaluated by the Matrigel assay, as previously described. With this assay 
it was possible to quantify the proangiogenic response in function of the 
length and extent of the capillary network formed after 1 day of incubation in 
cell culture medium without proangiogenic agents (figure 11-A), containing 
soluble VEGF (Figure 11-B) or microspheres loaded with VEGF (Figure 11-
C).  
 
 
Figure 11 : In vitro assay on Matrigel. The images (A, B, C) represent the vascular network formed 
after 6 hours of incubation: A) in the absence of VEGF, B) with free VEGF (20ng/ml), C) with 
microspheres containing VEGF 
. 
Finally, the graph in Figure 12, shows that the number of capillary structures 
formed in the presence of microparticles containing VEGF is equal to that 
obtained in the presence of the same amount of free VEGF. 
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Figure 12 :Number of intersections formed after 6 hours of incubation in the absence of VEGF, with 
free VEGF (20ng/ml) and with microspheres containing VEGF 
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4.2. Scaffold characterization 
In order to modulate the driving force that regulates the compaction of 
adjacent microspheres, we selected a suitable solvent-non-solvent pairs such 
that the solvent was more volatile than the non-solvent and the two were 
miscible with each other. In the specific case, the selected solvent was 
chloroform and the selected non-solvent was ethanol. The choice of 
chloroform (solvent) was dictated by its high ability to dissolve the PCL, the 
PLGA and its fast kinetics of evaporation; at the same time, the use of 
ethanol (non-solvent) has permitted a reduction of the power of chloroform 
dissolution.  
The effect of solvent concentration (mg MS/µl of solvent ) was studied and 
the results are shown in Figure 13, which depicts the effect of the 
concentration of the sintering solution on the degree of sintering between the 
microspheres.  
The scaffold sintered at concentrations less than 1% (W/V) did not survive 
demolding and were discarded from the analysis. The scaffold sintered with 
the 1% (W/V) solvent composition remained intact after demolding 
suggesting that the microspheres were indeed sintered even though it is 
difficult to see the region where the microspheres are joined together. As the 
concentration increases from 1% (W/V)  the bonding region between the 
microspheres becomes more evident. At a concentration of 2% (W/V) the 
sintering causes occlusion of the open porosity visible at lower 
concentrations.  
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Figure 13 : Micrographs at different magnification of scaffold sintered at different concentrations of 
solvent / non-solvent (ul / mg MS): a) 1%, B) 1.5% and C) 2%. 
 
The SEM analysis showed, in all samples, that the microparticles are 
distributed randomly, with points junction connection arranged uniformly 
throughout the volume ( Fig. 14, 15 and 16). 
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Figure 14 : Micrographs at two different magnifications of scaffolds made with microspheres in the 
range 300 to 355 µm. 
 
   
Figure 15 : Micrographs at two different magnifications of scaffolds made with microspheres in the 
range 355 to 425 µm 
 
   
Figure 16 : Micrographs at two different magnifications of scaffolds made with microspheres in the 
range 200 to 425 µm 
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It 'also evident from these micrographs, the formation of points junction, 
characterized by such dimensions as to ensure a high bond strength between 
the microspheres. These junctions, although are well developed and 
elongated, are confined in the neighborhood of the junction points, resulting 
in a fully interconnected structure.  
Bioactive scaffolds have been obtained through the compaction of PCL 
microparticles, obtained by single emulsion and PLGA\VEGF microparticles, 
obtained by the double emulsion, using the same parameters used for the 
realization of scaffold protein-free. 
The images obtained by confocal microscopy show that the microparticles 
containing the growth factor are uniformly distributed in the total volume of 
the scaffold and predicted a homogeneous release of the factor into the 
surrounding environment ( Fig. 17). 
 
Figure 17 : Sections of scaffold manufactured with pcl microparticles and plga/Rhod microparticles. 
The image show that the plga microparticles are uniformly distributed in the total volume of the 
scaffold 
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4.2.1. Porosimetric analysis by Micro-CT 
 
A qualitative and quantitative evaluation of the porosity was performed by 
analysis techniques of 3D images with the help of a computerized 
microtomograph. Through the images of the sections of the sample was 
possible to calculate some characteristic parameters of the structural 
properties of the scaffold (volume fraction, average pore size and pore 
distribution), based on the size of the individual pixels that defines the 
resolution of the image. The table 5 shows the values obtained from the 
analysis of images made using dedicated software (CTan): 
Scaffold Types Microsphere Diameter (µm) Total Porosity (%) 
Protein-free Scaffold 200-425 29.5 ± 2.1 
Protein-free Scaffold 355-425 36.46 ± 1.7 
Protein-free Scaffold 300-355 34.65 ± 2.2 
Protein-free Scaffold 200-300 33.30 ± 0.7 
Bioactive Scaffolds 200-425 30.23 ± 1.3 
Bioactive Scaffolds 200-300 34.76 ± 0.6 
Table 5 : Relationship between the size of the microparticles used and the porosity of the scaffolds 
produced as assessed by micro-CT 
 
The results show a total porosity decreasing with decreasing size of the 
microparticles used for the realization of the scaffold. Scaffold made with 
only the particles with broader range show a porosity of less than all the 
others and this may be attributable to the greater packing to which the 
microspheres are meeting and which result in a reduction of the total porosity 
of the scaffolds. 
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Passing from Scaffold protein-free to those bioactive, made with the same 
size range of microspheres, the total porosity does not vary, showing that the 
microspheres of PLGA not interfere with the packaging process. 
it was also possible to reconstruct the three-dimensional images of the cross 
sections of the sample using an appropriate software (CTVol) able to 
reproduce the original structure. Is shown below the relative structure of the 
scaffold protein-free obtained by sintering of microparticles with size range 
200 to 300 µm: 
 
Figure 18 : 3D representation of the scaffold protein-free obtained by solvent sintering of 
microparticles with a size range 200 to 300 µm. 
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4.2.2. Surface treatment 
 
The surface property of a material especially the degree of hydrophilicity or 
hydrophobicity plays a very important role in cell adhesion during the initial 
period of cell seeding. This determines the successful formation of tissue 
constructs leading to the subsequent cell proliferation, differentiation and 
new tissue in-growth.  
 
Because scaffolds are composed of PCL and PLGA, two highly hydrophobic 
polymers, to facilitate the process of cell adhesion and proliferation, were 
subjected to two types of treatments: chemical and plasma treatments.  
To study the effect of the different treatments, the water contact angles on the 
surface of scaffold were measured by a sessile drop technique, previous 
described (fig. 19). 
 
 
Figure 19 : Water contact angle images  at different time point on scaffold protein free untreated 
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The results of this analysis are listed as a function of time in Table 6. 
Time Point 
(Sec) 
untreated (± 
S.D.) 
EtOH\NaOH 
treated (± S.D.) 
Plasma treated  
(± S.D.) 
0 
93.787 ± 
3.601 
34.683 ± 8.407 4.806 ± 9.621 
15 
71.824 ± 
3.812 
0 0 
180 
21.442 ± 
3.342 
0 0 
Table 6  : Measured static contact angle data at different time point on untreated, EtOH/NaOH 
treated and plsma treated PCL scaffold surface. 
These results clearly show that chemical methods as well as plasma 
treatments are able to enhance the attachment and growth of cells. Plasma 
surface modification is  effective in enhancing cell–material interactions as a  
Ethanol\sodium hydroxide treatments. 
the greater hydrophilicity of the scaffold plasma treated compared with the 
scaffold alkaline hydrolysis treated, can be explained by the greater 
penetration of the plasma that resulted in a deeper modification of the surface 
with the introduction of a greater number of polar components, such as 
hydroxyl ( C OH), carbonyl ( C O), carboxyl [ (C O) OH] 
oxygen groups, on the scaffold surface and the cleaving of the C C and C
H bond in the polymers backbone. These polar functional groups not only 
increase the wettability and solid surface energy of the polymer surface but 
also improve the early cell attachment and protein adsorption. 
This hypothesis was also confirmed by the study of the treated surfaces 
through analysis of atomic force and scanning electron microscopy. The 
micrographs and the AFM images shown in figures 20, 21 and 22, show that 
while the treatment of alkaline hydrolysis involves no substantial change in 
the surface compared to the control, the plasma treatment causes a structural 
change of the surface, with the formation of numerous growths 
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Figure 20 : Micrograph and AFM image of the surface of the scaffold protein free untreated 
 
Figure 21 : Micrograph and AFM image of the surface of the scaffold protein free EtOH\NaOH 
treated 
 
Figure 22 : Micrograph and AFM image of the surface of the scaffold protein free Plasma treated 
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In order to observe the effect of surface treatment on the adhesion, 
proliferation, and differentiation behavior of cells, the HUVECs cells were 
cultured on the scaffold with different treatments. 
Regarding the morphology of the cells, at 6 hours after seeding, does not 
seem to vary a lot from one treatment to another (Figure 23). In particular in 
all three Scaffold all cells have a spherical shape with the presence of 
lamellipodia and filopodia.  
 
Figure 23 : Micrographs of cells on scaffolds: (A) untreated, (B) EtOH / NaOH treated and (C) 
Plasma treated. In all three micrographs the cells morphology is equal, indicating that the different 
treatments do not affect the morphology. 
 
 
Table 7 : type of treatment performed on the surface of the scaffold in function of cell adhesion 
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Conversely, to change is the number of cells (6 hours after seeding), that 
adhere on the surface of the scaffold. Reporting the type of treatment 
performed on the surface of the scaffold as a function of cell adhesion (Tab 
7) may be observed that, in both the scaffolds treated, cell adhesion is greater 
than the non-treated, in particular is maximum for plasma. This, as already 
pointed out above, may be due to the greater number of polar components 
and the increased roughness of the plasma surface treatment. 
4.2.3. Mechanical properties 
 
The mechanical strength of the scaffolds sintered, as well as the influence of 
the size of the microparticles used on such properties, was evaluated by 
mechanical compression test . The results obtained are reported in the 
following table: 
Tipologia Scaffold 
Diametro 
Microparticelle (µm) 
Modulo Elastico (Mpa) 
Scaffold Protein-free 200 - 425 4.26 ± 0.31 
Scaffold Protein-free 355- 425 2.36 ± 0.54 
Scaffold Protein-free 300 - 355 2.41 ± 1.7 
Scaffold Protein-free 200 - 300 2.73 ± 3.2 
Scaffold Protein-free 
EtOH/NaOH treated 
200 - 300 2.05 ± 2.74 
Scaffold Protein-free 
plasma treated 
200 -300 4.61 ± 2.31 
Table 8 : Relationship between the size of the microparticles used and the mechanical properties of 
the scaffolds made. 
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The samples tested show an elastic modulus of between 2 MPa and 4.5 MPa 
approximately. From the mechanical characterization performed on the 
untreated samples were not observed significant changes in the elastic 
modulus to vary the range of microspheres used, except in the sample with 
the range 200-425 which. This result can be attributed to the increase in the 
number of junction points and, therefore, of structural constraints in the 
structure of the scaffold. 
In the samples that were subjected to a surface treatment we can see that 
while in the scaffolds treated with EtOH/NaOH the elastic modulus does not 
vary compared to untreated, the scaffolds treated with plasma show a doubles 
value of the elastic modulus. This phenomenon can be attributed to the fact 
that the plasma treatment penetrates deeper into the polymer backbone, 
making it more rigid. 
 
4.2.4.  “In Vitro” Release kinetics from bioactive scaffold 
 
The release profile of VEGF by bioactive scaffold is shown in Figure 24 and 
is expressed as ng of VEGF/scaffold released in active form in function of 
time. We observe an initial release of VEGF, in the first day of incubation, 
rather slow (<6 ng/scaffold), followed by a controlled release of VEGF 
sustained for over a month. In particular, the scaffold are able to provide a 
constant release of VEGF of about 2.5 ng/scaffold daily for all period 
evaluated. 
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Figure 24 : Release profile of VEGF by bioactive scaffold (ng\scaffold) 
 
Graph 25 compares the kinetics of release of VEGF from individual bead and 
scaffolds, expressed both as ng VEGF/mg of microspheres. This comparison 
shows that the trend of the release kinetics is practically the same, but much 
slower for the beads inserted into the scaffold. This phenomenon can be 
ascribed to the process of sintering that through the formation of the junction 
points between microspheres, reduces the surface area available to the free 
factor. In addition, the tortuosity of the path to which the growth factor meets 
once released by the microsphere further slows its kinetics. 
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Figure 25 : Comparison between the release kinetics of VEGF from scaffolds and single 
microparticles (ng VEGF / mg MS) 
 
These results suggest that the bioactive scaffolds made from microparticles 
containing VEGF, previously described, have enormous potential in inducing 
the formation of new blood vessels and consequently to promote the 
formation of a highly vascularized tissue. 
 
4.2.5. Cell adhesion and proliferation studies 
 
Tests were carried out on cell invasion in the scaffold. On the surface of the 
scaffolds were seeded endothelial cells, as previously described. After one 
and seven days cellularizzati samples containing microspheres with and 
without VEGF were fixed with formalin. Subsequently, immunofluorescence 
was performed using phalloidin to stain the actin cytoskeleton in red and 
Sytox green to color the nuclei in green. The images were made with two-
photon confocal microscope. As can be seen in Fig 26, one day after the 
sowing we do not have a significant difference between free protein scaffolds 
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and bioactive scaffolds. In both cases, at the time a day, we can only evaluate 
the adhesive effect of the cells to scaffolds mediated by medium containing 
fetal serum.  
 
 
Figure 26 : Confocal microscopy images by staining with phalloidin (red) and Sytox green (green) 
of the scaffold protein free (A) and bioactive scaffold (B) a one day. 
After 7 days, however, the bioactive scaffolds have a homogeneous cell 
distribution and especially an increase of cells inside the scaffold compared 
to the time a day. it is noteworthy to point out that the scaffold protein-free 
has a lower number of cells when compared to the same time a day scaffold 
(Fig. 27). 
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Figure 27 : Confocal microscopy images by staining with phalloidin (red) and Sytox green (green) 
of the scaffold protein free (A) and bioactive scaffold (B)  a  7 days 
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5. Conclusions 
 
In this research work has been proposed and optimized an innovative 
approach for the realization of three-dimensional bioactive scaffold for the 
regeneration of bone tissue. This approach consists in the sintering of 
biodegradable Polycaprolactone microparticles and PLGA microspheres 
containing VEGF (bottom-up approach). 
The first stage of this work has been focuses on the study and optimization of 
the process of preparation of polycaprolactone microparticles. Through the 
use of the process of single emulsion has been possible to achieve spherical, 
non-porous and dimensions suitable microparticles, for their use in the 
process of sintering.  
Subsequently it is passed to the realization of PLGA microspheres able to 
release in a controlled manner the VEGF (Vascular endothelial growth 
factor) through the optimization of the process parameters of the double 
emulsion/solvent evaporation with which the microparticles were obtained. 
Such microspheres have been shown able to issue constant concentrations of 
GF in the time by means daily doses of about 0.5 ng / ml, in order to obtain a 
efficient proangiogenic stimulus. 
This research work then focused on the realization of three-dimensional 
scaffolds through chemical compaction (through the use of a suitable mixture 
of solvents) of the microspheres obtained and optimized in the first phase. To 
identify the optimal conditions of preparation, the scaffolds obtained by 
solvent sintering were fully characterized in terms of morphology (SEM, 
confocal microscopy, porosity, computed microtomography) and mechanical 
properties (compression test). 
To further improve the characteristics of such Scaffold, in terms of increased 
adhesion and cell proliferation, were made two types of surface treatments. 
From the comparison of these two treatments can be seen that both lead to an 
increase in the number of adherent cells, but in the case of treatment with 
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plasma was also able to improve the mechanical properties (from 2.73 to 4.61 
MPa). 
The last phase of this thesis concerned the study of the kinetics of growth 
factor release from scaffolds. Studies in vitro have clearly demonstrated that 
the scaffolds are made to have a huge potential in inducing the formation of 
new blood vessels and the formation of highly vascularized tissue. 
The use of a bottom-up approach has allowed the creation of structures with 
microstructural properties can provide adequate support to the regeneration 
of bone tissue and to guide this regeneration processes through the controlled 
release in space and time of VEGF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 79 
 
 
 
 
 
 
 
 
 
CHAPTER 2  
CONTROLLED RELEASE SYSTEMS OF NERVE 
GROWTH FACTOR FOR THE TREATMENT OF 
OCULAR DISEASE  
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1. Introduction 
Diseases of the eye vary from minor conjunctivitis to irreversible visual 
impairment caused mainly by diseases of the posterior eye. The most 
prevalent eye diseases which cause visual impairment include age-related 
macular degeneration, diabetic retinopathy, glaucoma, dry eye and retinitis 
pigmentosa. 
The increase in the number of patients affected by these diseases has 
determined, in recent years, a renewed in scientific and institutional interest 
in relation to these diseases. The causes of this increase are manifold. In first 
place, there is a progressive increase in life expectancy, which has led to the 
exponential growth of ocular diseases associated with aging. In addition the 
great scientific and technological progress of ophthalmology, in recent 
decades, has led to a reduction in patients destined to blindness. However, the 
number of patients with partial residual vision, insufficient to ensure 
complete autonomy has also increased. 
Currently, many pharmaceutical companies have focused their attention on 
the design of new pharmaceuticals systems for the treatment of these eye 
diseases. From cornea to choroid, new drugs have been formulated to address 
a great variety of ocular diseases.  
Yet without good drug delivery systems, these drugs are less effective than 
they could be, possibly even ineffective or able to cause serious side effects. 
This problem is caused in the eye due to the great differences in tissue types 
that need to be targeted for therapy in different disease situations and the 
significant uptake barriers posed by ocular structures and biochemical 
inactivation systems. These barriers include simple but effective 
sclera/corneal tissue constraints on drug entrance into the eye and the 
selective permeability of the blood–ocular barriers.  
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Another important aspect of drug delivery is “targeting.” To maximize 
efficacy and safety, drugs need to be directed as best as possible to a specific 
tissue or cell type once ocular penetration has been achieved. It is usually 
difficult to have the drug self-target, but a drug delivery system can 
sometimes be designed to achieve this goal. 
The first barrier of eye is the tear film. Less than 5% of most drugs delivered 
in this way enter into the eye and the remaining 95% is swept away through 
tear drainage. Certainly, drug modification and special compounding can 
significantly enhance penetration, but for drugs that are expensive, such 
delivery may not be justified especially, since this route generally does not 
allow for penetration back to the posterior segment. On the other hand, 
several techniques such as mixed micellar formulations are showing promise 
that drug delivery to the posterior segment can, in fact, be both practicable 
and practical.  
Beyond this, there are both hydrophilic and hydrophobic barriers to drug 
delivery through the cornea. The stroma is a good water barrier, while 
epithelial and endothelial cells function as effective lipid barriers with only 
partial penetration of biphasic/nonpolar drugs. 
For posterior segment disease, the most common route of delivery presently 
used is intravitreal injection. Advantage of this type of direct treatment is that 
a high level of drug is delivered to the retina. Negatives include the 
possibilities of infection, retinal detachment, the development of cataract or 
glaucoma, a relatively short time of action, and the lack of patient enthusiasm 
for such delivery. Nonetheless, frequent administration of drugs via this route 
can lead to retinal detachment, retinal haemorrhage, endophthalmitis and 
increased intraocular pressure. To minimize some of these complications, 
novel drug-delivery systems have been developed in the form of 
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biodegradable or non-biodegradable micro and nanoparticles, which can be 
placed long term in the vitreous. 
A particle systems offers several inherent advantages over other systems, 
such as naked injection of drug. For example, the composition, size, and 
surface properties of the particle can be controlled to give maximal drug 
content, penetration, and uptake as well as afford a level of protection against 
drug toxicity. Because of their size, one of the most interesting and useful 
properties of micro and nanoparticles is their potential ability to cross the 
blood–ocular barriers and their nature also allows for protection of the drug 
during transport, improving drug lifetime within the eye. To date, most of the 
materials used have been non degradable but advances are rapidly being 
made in the formulation of biodegradable substrata that could further enhance 
delivery as well as not leave behind a residual footprint. 
This project will be focused on the study of design, formulation, set up, 
characterization and production of micro and nanoparticles’ systems for the 
controlled release of Nerve Growth Factor (NGF), that appears to play a 
crucial role in the treatment of various eye diseases. 
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1.1.  Ocular Anatomy  
The eye is an isolated sensory organ consisting of diverse tissue and cell 
types. The basic structure (Fig. 1) is essentially a globe consisting of three 
concentric layers. The outermost layer is called the fibrous tunic and is 
divided into the cornea and the sclera. Inside this external covering is the 
vascular tunic or uvea, consisting of the iris and the adjacent ciliary body in 
the anterior segment and the choroid in the posterior segment of the eye. 
These structures are responsible for ocular nutrition through the systemic 
blood supply. Finally, the innermost layer is the nervous tunic, mainly 
consisting of the neural retina. Within these concentric layers are the fluid or 
gel-containing reservoirs: the anterior chamber and the smaller posterior 
chamber, containing the aqueous humor and the larger vitreous cavity filled 
with vitreous gel. The anterior segment is mainly composed of the cornea, 
lens, iris, ciliary body and aqueous humor, while the posterior segment 
comprises the photoreceptive retina, posterior sclera, choroid and vitreous 
humor. The lens divides the two segments, and is common to both
77
. 
1.1.1. The Cornea 
The cornea forms the strongest refractive entity of the eye, contributing two-
thirds of the refractive power of this organ
78
. It is completely avascular and is 
composed of three main layers. These layers, beginning at the anterior of the 
cornea are the epithelium, the stroma, the endothelium. The stroma makes up 
90% of cornea's structure and is composed of collagen fibers, proteoglycans 
and approximately 78% water. Without interweaving, the collagen fibers are 
laid down at right angles to each other. This arrangement allows for the 
transmittance of 99% of incident visible radiation. The corneal surface is 
bathed in a thin tear film that helps to protect the eye from irritants and 
noxious substances and also acts as an effective drug barrier, quickly diluting 
and sweeping away drops applied to the eye.  However, the cornea is the 
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principal route into the eye for topically applied drugs even though it serves 
as a major barrier to drug absorption, affording both a physical barrier and a 
metabolic barrier to substances that might enter the eye. The cellular structure 
of the cornea along with the tear film pose both hydrophilic and lipophilic 
barriers to substance penetration. Penetration is difficult due to zonula 
occludens, or tight junctions between the epithelial cells. The hydrophobic 
nature of the corneal epithelium is probably the greatest impediment to 
intraocular drug bioavailability. Interestingly, the cornea is rich in nerve 
fibers but is avascular. Thus, in spite of the substantial uptake barriers that 
keep out unwanted substances, the lack of vascularization necessitates the 
selective uptake of nutrients (including oxygen) through the tear film or the 
aqueous humor. On the positive side for getting drugs into the eye, the cornea 
expresses specific transport systems that can facilitate drug entrance into (or 
out of) the tissue. Physically, the cornea is striate in nature, consisting of five 
discrete layers, two of which are laminar cell layers. This essentially makes 
the cornea a lipid–water–lipid sandwich. On the surface are epithelial cells 
attached to a layer of basement membrane called Bowman’s membrane, a 
laminate structure mainly composed of collagen fibers. This pairing is one of 
the first lines of defense of the eye, forming a barrier that is difficult to 
penetrate. Underneath the epithelium is a thick layer of matrix material called 
the stroma. It is mainly acellular with only a few cells, such as keratocytes, 
and is about 500 microns thick, accounting for about 90% of the corneal 
thickness. It is composed of mostly water (~80%), regularly arrayed collagen 
fibers (~15%), and mucopolysaccharides (~5%). Finally, on the interior 
surface is a layer of endothelial cells attached to Descemet’s membrane. It is 
a latticework of collagen fibers coming together in a nodal pattern. It acts as a 
barrier to the entrance of potentially toxic organisms into the eye but allows 
for passage of water and nutrients. The endothelium is composed of simple, 
mostly hexagonally shaped cells, only a single cell layer in thickness. 
However, it performs the important task of fluid regulation for the stroma, 
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maintaining a state of deturgescence, compacting the collagen fibers and 
maintaining tissue transparency. Physiologically, it has no true elastic fibers 
and thickens with age (birth: 3 microns; adult: 12 microns; aged: up to 30 
microns). There is a barrier in the endothelium to penetration by aqueous 
humor, that is, a tight seal, composed of macula occludens junctions. 
Endothelial cells are rich in mitochondria to produce the energy needed to 
pump sodium and water out of the cornea to maintain proper thickness and 
thus transparency. 
1.1.2. The Lens 
The lens is the transparent biconvex epithelial tissue that is responsible for 
accommodation and refraction of light. This structure is avascular and is 
made up of a dense inner cortex and an elastic outer capsule. The bulk of the 
lens is made up of elongated lens fiber cells which are precisely aligned to 
maintain transparency and a high refractive index. 
1.1.3. The Iris 
The iris is a colored muscular tissue attaching peripherally to the ciliary 
body. It controls the amount of light entering the pupil. The iris also divides 
the anterior segment into the anterior and posterior chambers. The stroma of 
the iris contains the dilator and sphincter muscles. The dilator muscle relaxes 
the iris to increase the amount of light that enters the pupil, while the 
sphincter muscle constricts the iris to achieve the opposite effect.  
1.1.4. The Ciliary Body 
The ciliary body is located between the choroid and iris. It is divided into two 
sections, the anterior pars plicata and the posterior pars plana. The pars 
plicata comprises the ciliary muscles and ciliary processes. The ciliary 
muscles are attached to the zonules of the lens by the ciliary processes. These 
muscles pull on the zonules to change the shape of the lens in order to adjust 
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the accommodation. In addition to connecting the ciliary muscles to the 
zonules, the ciliary processes also produce the aqueous humor that flows into 
the anterior chamber through the pupil.  
1.1.5. The aqueous humor 
The aqueous humor is a flowing fluid that fills the anterior chamber, the 
space between the cornea and iris. This fluid is produced by the ciliary 
processes and is ejected through the trabecular meshwork into the canal of 
Schlemm which leads into episcleral veins. The ciliary processes of the 
human eye produce aqueous humor at a rate of 2 to 2.5 μL/min. The 
production of the aqueous humor results in the intraocular pressure (IOP) of 
the eye. The composition of the aqueous humor is similar to that of blood 
plasma. A major function of the aqueous is to provide nutrients for the cornea 
and lens.  
1.1.6. The Retina 
The retina is the light sensory tissue which lines the posterior two-thirds of 
the eye.  It contains the photochemicals and neurologic connections which 
convert the light entering the eye to neural impulses that are relayed to the 
brain via the optic nerve. The retina is supplied with blood by a layer of large 
choroidal vessels and capillaries. Immediately inside this vascular layer is the 
retina pigment epithelium (RPE) layer and the inner neurosensory layer 
(rods, cones and ganglion cells). The RPE is a single layer of tightly joined 
cells which forms a barrier that prevents the diffusion of some substances 
between the choroid and the neurosensory layer. The photoreceptor cells of 
the retina are the rods and cones. The rods, the majority of which are in the 
periphery of the retina, are responsible for peripheral and low luminance 
vision. The cones, clustered mainly in the macula, provide color vision and 
central detailed vision. Inner to the rods and cones is the bipolar layer which 
serves as neural transmitters to the ganglion cell layer. The ganglion cell 
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layer is the last neural connector which converges to form the optic nerve that 
ultimately transmits the neural impulses.  
1.1.7. The Choroid 
The choroid is the dense network of blood vessels that covers the retina. 
These blood vessels are of two types. The first category is the 
choriocapillaris, which are small capillaries that form the innermost layer of 
the choroid. The second group of blood vessels is composed of larger arteries 
and veins, which are posterior to the choriocapillaris. The blood flow from 
the choroid provides nutrients to the RPE. 
1.1.8. The Sclera 
The sclera is the white colored part of the eye. This tissue is composed 
mainly of collagen fibers. disorganized manner. This haphazard arrangement 
results in the opacity of the sclera. The main function of this tissue is to 
provide a protective layer for the internal components of the eye. 
1.1.9. The Vitreous Humor 
The vitreous humor is a transparent, gel-like structure that accounts for about 
four fifths of eye’s volume. Towards the anterior segment of the eye, it is 
bordered by the lens, zonules and ciliary body. In the posterior segment, the 
vitreous humor is enclosed by and adjoins the retina. It serves as a 
mechanical buffer for the surrounding tissues, and assists in the maintenance 
of intraocular pressure. Transparency of the vitreous body provides an 
uninhibited path for light to be transmitted to the retina. 
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1.2. Ocular Diseases  
Many sight threatening diseases occur within the posterior segment causing 
vision impairment and even irreversible blindness [6]. Some of these diseases 
include age-related macular degeneration (AMD), retinitis pigmentosa, 
endophthalmitis, and diabetic retinopathy. 
1.2.1 Age-related Macular Degeneration  
Age-related macular degeneration, or AMD for short, affects the macula in 
people over the age of 50. The macula is the part of the retina that lies in the 
back of the eye and is responsible for fine detailed central vision. This 
disease causes progressive deposition of abnormal material called “drusen” 
within the macula. Over time, it may progress into two main clinical forms, 
namely the “dry” and “wet” forms. Either can lead to sight loss. The “dry” 
form occurs when there is progressive loss of cells in the macula area. In this 
case, there is usually a gradual deterioration of vision and it may take several 
years before vision is significantly affected. The “wet” form occurs when 
there is abnormal growth of blood vessels within the macula area. These 
blood vessels usually leak fluid, or may bleed and develop a scar. In this case 
there is usually rapid progression of visual loss (90% chance of severe visual 
loss in the affected eye within 2 years). Some individuals with “dry” disease 
may go on to develop “wet” disease. 
1.2.2 Retinitis Pigmentosa 
The Retinitis Pigmentosa (RP) is a retinal degenerative disease that affects 
the photoreceptors (rods and cones) the cells which, when hit by light, 
transform your image into an electrical pulse that travels along the optical 
paths to reach the brain where are interpreted. This is a hereditary disease that 
is transmitted genetically by the Legge of Mendel. It is caused by a genetic 
mutation that causes a defect in loading of photoreceptors that degenerate, 
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causing progressive loss of vision. The risk of having sick children depends 
on the type of inheritance. 
1.2.3 Endophthalmitis 
Endophthalmitis is an inflammatory condition of the intraocular cavities (ie, 
the aqueous and/or vitreous humor) usually caused by infection. 
Noninfectious (sterile) endophthalmitis may result from various causes such 
as retained native lens material after an operation or from toxic agents. The 2 
types of endophthalmitis are endogenous (ie, metastatic) and exogenous. 
Endogenous endophthalmitis results from the hematogenous spread of 
organisms from a distant source of infection (eg, endocarditis). Exogenous 
endophthalmitis results from direct inoculation of an organism from the 
outside as a complication of ocular surgery, foreign bodies, and/or blunt or 
penetrating ocular trauma.  
1.2.4 Diabetic Retinopathy 
Diabetic retinopathy is retinopathy (damage to the retina) caused by 
complications of diabetes, which can eventually lead to blindness. It is an 
ocular manifestation of diabetes, a systemic disease, which affects up to 80 
percent of all patients who have had diabetes for 10 years or more. 
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1.3 Nerve growth Factor 
Nerve growth factor (NGF) is the first discovered member of the 
neurotrophin family
79
.  NGF is essential for the development and phenotypic 
maintenance of neurons in the peripheral nervous system (PNS) and for the 
functional integrity of cholinergic neurons in the central nervous system 
(CNS)
80
.  
The aminoacid and messenger RNA sequences of this neurotrophin have 
been classified and indicate that NGF is a highly conserved molecule that 
shares considerable homology within different species
81
. The mature,  active 
form of NGF descend from proteolitic cleavage of a precursor form 
(ProNGF), that have important roles during development and in adult life, 
having both pro-apoptotic and neurotrophic properties
82
. 
NGF exerts its biological action by challenging the specific receptor 
tropomyosin kinase receptor A (TrkA), which is a typical tyrosine kinase 
receptor
83
. The major cytosolic/endosomal pathways activated by the TrkA 
are Ras-mitogen activated protein kinase (MAPK), extracellular signal-
regulated kinase (ERK), phosphatidylinositol 3 kinase (PI3K) -Akt, and 
Phospholipase C (PLC) -γ 84. NGF also binds to and activate the low affinity, 
non-selective p75 pan-neurotrophin receptor (p75NTR). This receptor is a 
transmembrane glycoprotein that regulates signaling through TrkA
85
; binding 
of NGF to p75NTR activates additional signaling pathways that, in the 
absence of co-expressed TrkA, may signal a cell to die via apoptosis
86
. 
Signaling pathways   by p75NTR are the Jun kinase signaling cascade, NF-
κB and ceramide generation87. 
The discovery of NGF dated the ‘50s of the last century and was awarded 
with the Nobel prize in 1986.  In 1953, Rita Levi-Montalcini, working in the 
Victor Hamburger laboratory at Washington University (Saint Louis, MA, 
USA), grafted a piece of mouse sarcoma tissue in to chick embryos whose 
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wing buds had been extirpated. She discovered that the tumor tissue produced 
a soluble factor that promoted the growth of nearby sensory and sympathetic 
ganglia. Collaborating with the biochemist Stanley Cohen, they isolated the 
substance responsible and named it NGF. For over 35 years, NGF has been 
considered as a very powerful and selective growth factor for sympathetic 
and sensory neurons and for cells derived from the neuronal crest
88
.  
   
Figure 28 : The huge amount of research data produced since its discovery in the 1950s 
 
In these neurons, NGF dynamically controls neurotransmitters and 
neuropeptides synthesis. In sympathetic neurons the production of 
norepinephrine is regulated by NGF through selective induction of tyrosine 
hydroxylase (TH)
89
. In the dorsal root ganglion (DRG) the expression of 
neuropeptides such as Substance P (SP) and Calcitonin Gene-Related Peptide 
(CGRP) by primary sensory neurons is under NGF control and in vivo 
deprivation of NGF, as a result of nerve transection or anti-NGF treatment, 
causes a marked decrease in SP and CGRP synthesis
90
. 
NGF supply from the innervation field influences the neuronal plasticity that 
allows the adult nervous system to modify its structure and functions in 
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response to stimuli. Indeed, the constitutive synthesis of NGF in adult tissues 
correlates with PNS neurons phenotypic features, such as innervation density, 
cell body size, axonal terminal sprouting, dendrites arborization, induction or 
inhibition of neuropeptides and neurotransmitters or transmitter-producing 
enzymes
91
. 
In the central nervous system (CNS), the greatest amount of NGF is produced 
in the cortex, the hippocampus and in the pituitary gland; although significant 
quantities of this neurotrophin are also produced in other areas, including the 
basal ganglia, thalamus, spinal cord and in the retina
92
. The NGF plays a 
pivotal role in the survival and function of cholinergic neurons of the basal 
forebrain complex (BFC)
93
, such functions include attention, arousal, 
motivation, memory and consciousness. Since BFC neurons are highly 
affected in Alzheimer’s disease (AD), NGF has been indicated as a potential 
protective and/or curative factor for neurodegenerative disorders associated 
with these neurons
94
. In the CNS, NGF also regulates phenotypic features in 
noradrenergic nuclei of hypothalamus and brainstem, participating in the 
central regulation of autonomic response and in the modulation of stress axis 
activity. 
Cells of the immune-hematopoietic system also produce and utilize NGF. 
Since the early description of the effects of NGF on mast cells, the role 
played by the neurotrophin in the regulation of immune functions and 
immune cells behavior has been greatly characterized. NGF receptors are 
expressed in immune organs and on immune cell populations allowing NGF 
to modulate cell differentiation and regulate the immune response
95
. NGF 
affects the survival and/or differentiation and/or phenotypic features of 
hematopoietic stem cells, granulocytes, lymphocytes and monocytes. NGF 
concentrations in the tissues change during inflammation and inflammatory 
mediators induce NGF synthesis in a variety of cell types. Enhanced 
production of NGF has been reported in inflamed tissues of patients with 
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inflammatory and autoimmune diseases
96
 but the reasons why NGF 
concentration is enhanced and how this can affect inflammatory responses 
are far from being fully understood. 
1.3.1 Nerve growth factor in the eye 
1.3.1.1 Anterior Segment 
The first demonstration of the presence of NGF in the anterior segment of the 
eye dates back to 1980-1983 when Ebendal demonstrated for the first time 
the presence of NGF in the iris of the adult rat (5-10 pg / iris NGF). By 
studying the interactions between the sympathetic nerve endings and sensory 
target organs, Ebendal demonstrated that surgical denervation of sensory and 
/ or sympathetic resulted in an increase in the amount of NGF in the iris, the 
greater the sensory denervation with respect to symphathetic. These 
observations suggested that the sensory nerves would influence the levels of 
NGF in the territories of innervation through uptake / removal of the factor or 
feedack exerting a negative impact on the production or use of NGF. 
Ebendal also noted a sharp increase in NGF in the iris of the rat isolated and 
placed in culture. On the basis of this observation, Barth observed an increase 
in the iris in culture of NGF to 200 times compared to normal values in vivo 
and release of a factor in the medium. Also showed that the increase of NGF 
in culture derived from a synthesis and release by the iris, in fact, the 
production of NGF was blocked by inhibitors of the synthesis and mRNA 
transcription. One could therefore hypothesize several mechanisms 
responsible for the observed after NGF removal or denervation of the iris: an 
increase in the synthesis of NGF and / or a reduction in its degradation or 
removal from the cut nerve endings. 
In 1986 Heuman demonstrated in vitro increased levels of mRNA for NGF in 
the iris of the rat formally proving that it was the same iris to increase the 
production of NGF in culture. Contrary to the data on the in vivo studies, the 
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results of Shelton of iris in culture confirmed a significant increase in the 
levels of NGF messenger in the iris tissue and the author concluded that the 
significant increase in the expression of NGF gene was primarily responsible 
for the sharp increase in NGF observed in the iris in culture. 
Based on the evidence that NGF was a key molecule in the interaction 
between certain types of neurons and their target tissues,  in 1985. The 
injection of NGF into the anterior chamber of the eye leading to an increase 
of production of substance P by the iris, mimicking the effects of 
sympathectomy, and also an increase in the activity of tyrosine hydroxylase 
with a slight increase in Acht. 
In order to investigate whether also the neurotransmitters could influence the 
production of NGF by the target tissues of the nerves Hellweg studied the 
effects biogenic amine neurotransmitter and neuropeptide synthesis of NGF 
on the concentration and comparing the reaction to the trauma caused by 
dissection iris. Among the many substances tested none was able to induce 
strong initial increase in the synthesis of NGF observed in culture. In addition 
Hellweg proved that cutting the iris in culture in small pieces the production 
of NGF increased two hundred and fifty times the control, showed that this 
increase was the iris trauma primarily responsible for the observed transient 
increase of NGF. Subsequently we began to assess the presence and the 
function of NGF also level of the ocular surface. The first evidence of the 
presence of NGF at the level the corneal got Ebendal studied the levels of 
NGF mRNA in the chicken embryos
97
. She was later demonstrated the 
presence of NGF in the corneal epithelium and endothelium and in 
keratocytes in the human cornea and in the adult rat , these same cells were 
able to directly synthesize NGF. These observations suggested a role of NGF 
in tropism and in maintaining the integrity of the corneal epithelium in basal 
conditions
98
. 
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Employing a model experimental lesion of the corneal epithelium has been 
demonstrated that tissue reacts with a corneal insult mechanical corneal 
increased levels of NGF, due to the direct synthesis by the same cornea. 
These evidences show that NGF represents a corneal layer one molecule of 
"communication" between the sensory innervation and epithelial cells, 
influencing each other's function and tropism in a manner similar to that 
observed in the iris tissue.  
The corneal ulcers are caused by the loss of corneal sensory innervation and 
are accompanied by a reduction in the sensitivity to repeated 
disepitelizzazioni with ulcer formation seriously affecting visual function. 
For this condition does not exist at effective drug therapy. The topical 
administration of NGF resulted in a re-epithelialization of the ulcer with a 
recovery of corneal sensitivity of all patients treated without local or systemic 
side effects important, during or after the treatment. Recently, in addition to 
the role of NGF in the pathophysiology of the cornea and the iris, it has been 
demonstrated a potential role of this neurotrophin on other tissues of the 
anterior segment of the eye (crystalline lens and ciliary body) in addition to 
the presence NGF in the aqueous humor. 
 
Figure 29 : NGF and Visual system 
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1.3.1.2 Posterior Segment 
Some growth factors, and between these NGF, act on cells of the retina both 
during development and in the adult state. The synthesis of NGF and the 
presence of specific receptors was found in the retina of the chick embryo
99
 
and rats developing, where NGF appears to play a crucial role in the 
development and differentiation of the retina. Following the production of 
NGF has been demonstrated by the ganglion cells, Muller cells in the retina 
and pigment epithelium of adult rats
100
 , and has been highlighted the 
presence of NGF receptors also on cells of the retina of adult rats : pigmented 
epithelium and Muller cells, ganglion cells and Muller cells
101
. Also has been 
demonstrated the presence of anterograde and retrograde transport of NGF 
receptor by the ganglion cells in the rat. 
The addition of NGF to the culture medium of human RPE cells induce an 
increase in intracellular calcium levels and changes in the shape and intra-
cytoplasmic distribution of actin, indirect indices of stimulation to 
proliferation and cell migration 
102
.  Moreover, in a study of a mutant strain 
of mice, the administration of NGF that was able to delay the degeneration of 
photoreceptors. 
Several studies have evaluated the action of NGF on the growth and 
differentiation of  retina in vitro. Numerous studies in animal models have 
focused on the role of NGF in protecting   ganglion cells by a mechanical or 
ischemic damage. All work showed an efficacy of neuropeptide inhibiting the 
degeneration of these cells, in particular the study on rats showed that 
treatment with NGF allows survival of ganglion cells and nerve fibers of the 
optic nerve for about 7 weeks, has shown that in an experimental model of 
ocular hypertension in the rabbit the administration of NGF leads to a 
reduction of the loss of ganglion cells, on the other hand, the administration 
of anti-NGF, which inhibit the action of endogenous NGF, increase the 
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retinal damage induced hypertension. The results of this study suggest a 
protective role of NGF  on retinal ganglion cells subjected to hypertensive 
damage. 
1.3.1.3 Retinal and Optical Nerve 
Some growth factors, and between these NGF, act on cells of the retina both 
during development and in the adult state. The synthesis of NGF and the 
presence of specific receptors was found in the retina of the chick embryo 
[51] and rats developing, where NGF appears to play a crucial role in the 
development and differentiation of the retina. 
Following the production of NGF has been demonstrated by the ganglion 
cells, Muller cells in the retina and pigment epithelium of adult rats [52] , and 
has been highlighted the presence of NGF receptors also on cells of the retina 
of adult rats: pigmented epithelium and Muller cells, ganglion cells and 
Muller cells [53]. Also has been demonstrated the presence of anterograde 
and retrograde transport of NGF receptor by the ganglion cells in the rat. 
The addition of NGF to the culture medium of human RPE cells induce an 
increase in intracellular calcium levels and changes in the shape and intra-
cytoplasmic distribution of actin, indirect indices of stimulation to 
proliferation and cell migration [54].  Moreover, in a study of a mutant strain 
of mice, the administration of NGF that was able to delay the degeneration of 
photoreceptors. 
Several studies have evaluated the action of NGF on the growth and 
differentiation of retina in vitro. Numerous studies in animal models have 
focused on the role of NGF in protecting   ganglion cells by a mechanical or 
ischemic damage. All work showed an efficacy of neuropeptide inhibiting the 
degeneration of these cells, in particular the study on rats showed that 
treatment with NGF allows survival of ganglion cells and nerve fibers of the 
optic nerve for about 7 weeks, has shown that in an experimental model of 
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ocular hypertension in the rabbit the administration of NGF leads to a 
reduction of the loss of ganglion cells, on the other hand, the administration 
of anti-NGF, which inhibit the action of endogenous NGF, increase the 
retinal damage induced hypertension. The results of this study suggest a 
protective role of NGF on retinal ganglion cells subjected to hypertensive 
damage. 
 
1.3.1.4 Nerve Growth Factor in Ocular Disease 
In recent years, numerous studies year demonstrated that the retinal cells are 
sensitive to the action of NGF.  In 1979, Turner and Delaney first 
demonstrated that NGF is able to reduce or avoid the damage of the retinal 
cells after resection of the optic nerve. Recently, other studies have shown 
that the NGF administration induces functional recovery of the retinal 
ganglional cells in an animal model of acute retinal ischemia
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. In this study, 
visual acuity and contrast sensitivity were comparable normal animal and 
also a significant number of cells were protected from ischemic injury after 
administration of NGF. The mechanism basis of this effect is not clear 
although it has been speculated that the NGF reduces l' entry of calcium ions 
in retinal neurons after protecting ischemia in this way from being damaged. 
Another explanation is that the possible NGF can interfere with the 
mechanisms that regulate apoptosis. In support of this hypothesis has been 
demonstrated that NGF reduces the ganglional cell apoptosis after resection 
of the optic nerve in newborn rats. It is also possible that the protective role 
of NGF on the cells of visual system is a part of a cascade of events that 
involve the interaction between different cell types such as neurons, glia, 
retinal pigment epithelium, opening interesting therapeutic prospects for 
degenerative diseases currently no effective treatments, such as the 
degeneration age-related macular, diabetic retinopathy, retinitis pigmentosa 
and glaucoma. 
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1.4 Drug Delivery Systems into the Vitreous 
The administration of drugs and proteins in the district of the back of eye can 
be carried out through four possible routes: topical, systemic, intraocular and 
periocular. In the case of topical administration, the difficulty of the drug to 
penetrate through the cornea, aqueous humor and the lens, almost always 
involves non-therapeutic levels of the drug to the retina. The blood ocular 
barriers, consisting of the blood aqueous and blood retinal barriers, are the 
main obstacle for the effective treatment of most intraocular diseases by drug 
delivery using the systemic route. This route requires the administration of 
large doses of drugs to achieve therapeutic levels in the vitreous-retina, and 
can be associated with significant systemic side effects. The periocular drug 
delivery sites, are also hindered by the blood ocular barrier, but require 
smaller amount of drugs than the systemic route, and sometimes can achieve 
therapeutic drug levels in the vitreous-retina with lower systemic side effects. 
Nevertheless, poor penetration of many drugs into the eye not only limits the 
number of medications available for the treatment of ocular diseases, but also 
limits the extent to which those available drugs can be used without incurring 
undesirable systemic side effects. Therefore, due to the poor accessibility of 
some drugs to the vitreous by indirect routes, the direct intravitreous delivery 
of drugs is required for the effective treatment of some posterior segment 
diseases. 
When you want to administer active principles or proteins to the retina, the 
most simple and direct way is given by intravitreal injection. This type of 
administration has the advantage that the active principle remains localized 
and the exposure to the systemic circulation is very limited, because impeded 
by several barriers present. The second advantage is given by the relative 
safety of this method and by the increasingly minimally invasive surgical 
procedures in which the patient must undergo. 
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Moreover, since the eye is a confined organ and the vitreous humors is a 
gelatinous character, we could say that the vitreous can be considered as a 
"reservoir" of drugs, particularly those with higher molecular weight, because 
the ILM can be considered a barrier only to molecules greater than 40 kDa. 
As amply shown, the elimination of substances from the vitreous can occur 
through two main roads: posterior (active route) and anterior (by aqueous 
humors). Importantly, large molecules such as antibodies are removed 
through the posterior path and appear to pass the ILM. 
The speed with which a drug is eliminated from the vitreous is dependent on 
the one hand by its diffusivity and the other from its retinal permeability. 
Obviously, the structural state of the vitreous affect the elimination, as well 
as the integrity of the ocular barrier will affect its retinal permeability. From 
this it follows that the half-life of free large molecules inside the vitreous can 
be up to 4-5 days. 
Most attractive is the fact that the human vitreous represents about 80% of 
the eye volume (around 4 mL), offering a wide liquid empty space for the 
delivery of implants or devices with limited interference with vision. 
The limits to the drug delivery in the vitreous humor depending on the 
physicochemical properties of the drug and on the liquefaction state of the 
vitreous, the drug might not diffuse homogenously and high, even toxic 
concentrations could be reached focally. Once in the vitreous, active 
compounds may not diffuse passively into the retina and some retinal cells 
may not be targeted efficiently through intravitreous injections. 
Being anionic, polycationic formulations may form aggregates and induce an 
inflammatory reaction. Other high-molecular-weight positively charged 
molecules may be unstable in the vitreous, and protection against degradation 
may be required. Retinal inflammation and glial cells activation may result 
from any intervention into the vitreous or with polymers or their bioproducts, 
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which interfere with the drug activity per se. Finally, rarely, tractions induced 
by implants or injection procedures themselves may create retinal traction, 
tears, and retinal detachment. 
To minimize some of these complications, novel drug-delivery systems have 
been developed in the form of biodegradable or non-biodegradable micro- 
and nanoparticles, which can be placed long term in the vitreous. 
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2. Materials and Methods 
2.1. Materials 
The acid poly (D, L-lactic-co-glycolic acid) (PLGA) 50:50 (Resomer ® RG 
504H, i.v. 0:32 to 0:44 dl/g) was purchased from Evonik® (Germany). The 
poloxamer188 (Pluronic ® F68, Mw 8400, HLB 29), the polycaptolactone, 
the polyvinyl alcohol (Mowiol 40-88) bovine serum albumin (BSA), heparin 
sodium salt (Hp), Vitamin E TPGS, Lisozyme and phosphate buffer (0.01M 
Na2HPO4, 0.0027 M KCl and 0.137 M NaCl, pH 7.4) were purchased from 
Sigma Aldrich (USA). The NGF growth factor was donated by Dompé 
(Aquila, Italy). The ELISA kit for the quantitative determination were 
provided by Biotech (California, USA). All solvents used are of analytical 
grade and HPLC grade and were supplied by Sigma Aldrich (USA). The 
water used was filtered through 0.22 μM filter (Millipore, USA). 
 
2.2. Methods 
 
2.2.1. PLGA microparticles for controlled release of NGF 
 
The PLGA microparticles containing NGF were prepared by a modified 
multiple emulsion/solvent evaporation technique (W/O/W) with different 
theoretical loading and stabilizing agents. This multiple emulsion consists of 
a three-phase system in which the oil droplets, containing an internal aqueous 
phase, are dispersed in an external aqueous phase. The preparation method 
consists of two stages of emulsion that allow to encapsulate a drug 
efficiently. 
Briefly, a sterile buffer solution (50 mM NaH2PO4 .H2O, 100 mM NaCl, pH 
7.2) containing Nerve Growth Factor (conc. 0.98mg/ml) stabilizing agent and 
polyetilenglycol 400 in the ratio 1:40:1 (v/w/v) was emulsified by 
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homogenization at 17.500 rpm for 1 minutes (Ultraturrax T25 Basic, probe 
8G, IKA, Germany), in 2.5 ml of a solution of PLGA in Ethyl Acetate (20% 
w/v). The emulsion thus obtained was added  to the external phase consisting 
of 5 ml of an aqueous PVA solution (2% w/v) (Mowiol® 40-88) doped with 
300 µl of Ethyl Acetate, and emulsified by homogenization at 8.500 rpm for 
40 minutes. At the end, this double emulsion was added to trehalose water 
solution (5% w/v) and subjected to agitation by electronic stirrer (RZR 2102, 
Heidolph, Germany),  at 500 rpm for 3 hours, at room temperature, in order 
to facilitate the evaporation of the organic solvent and the precipitation of the 
polymer in the form of microparticles. Thereafter, the microparticles were 
isolated and washed with 30 ml of distilled water 4 times, by centrifugation at 
6000 rpm for 15 minutes at 4⁰C and subsequently subjected to a 
lyophilization cycle of 24 hours (0,001 atm , -60°C ) (Freeze Dryer Alpha 1-4 
LD plus, Martin Christ, DE). 
Different formulations are made varying the water phase of first emulsion, 
using various types of stabilizing agent to protect the nerve growth factor. 
The principal stabilizing agent used were: Bovine Serum Albumin, 
Lysozyme, Heparin and Vitamin E. 
Type Stabilizing Agent 
Theoretical Loading % 
(mg NGF\100mg MS) 
Micro A HSA, PEG400 
0.0098, 0.0147,  
0.0196, 0.049 
Micro B Heparin, HSA and PEG400 0.0098 
Micro C Vitamin TPGS 0.0098 
Figure 30 : Type and properties of microparticles containing NGF 
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2.2.2. Dimensional and Morphological analysis of microparticles 
 
a) Scanning electron microscopy observation 
The morphology and the internal structure of the microspheres was visualized 
using scanning electron microscopy (SEM) (Zeiss, FEG Ultraplus, 
Germany). A small quantity of plain microspheres was sprinkled on the SEM 
stubs and coated using a SEM coating system (Cressingthon, 208 HR, UK) 
with 10nm of platinum-palladium under an argon atmosphere. Samples were 
then observed for their surface morphology by SEM and photographs were 
taken at 5 Kv and different magnification. One stub was made for each batch 
and many pictures were taken of each stub.  
b) Confocal microscopy observation 
The distribution of HSA-Rhod and NGF-Flu within the microparticles 
was assessed by analysis by confocal microscopy (STED) (Leica TCS 
SP5 II), with Zeiss lens 20X / 3 NA (Carl Zeiss, DE). Different pictures 
and z/ stacks were taken for all type of microparticles formulated. 
 
c) Particle size analysis 
The average diameter and the particle size distribution was determined using 
a laser granulometer (Mastersizer 2000, Malvern Instrument, UK) from 
previously lyophilized microspheres suspended in an aqueous solution of 
PVA 0.5% (w/v). For each formulation the average diameter of the particles 
was expressed in microns ± standard deviation (SD) of the measurement 
carried out on three different batches of microspheres. 
 
2.2.3. Encapsulation efficiency  
The amount of total protein and NGF encapsulated within the microparticles 
was determined by degradation of the polymer matrix by extraction method. 
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Ten mg of microspheres was suspended in 1 ml of Ethyl Acetate\Buffer 
solution (50 mM NaH2PO4 .H2O, 100 mM NaCl, pH 7.2) and vortexed at 
room temperature for about 30 sec. The solutions were centrifuged at 4500 
rpm for 15 minutes at 4°C, and the supernatant analyzed for the content of 
proteins. 
For the analysis of the total amount of proteins present in the different types 
of realized microparticles was used a spectrofluorometric assay 
(FluoroProfile Kit, Sigma Aldrich) while for the analysis of NGF was used 
an specific immunofluorescence assay ELISA (Enzyme-linked 
immunosorbent assay). 
For the total amount of protein was used the FluoroProfile quantification kits 
as per the manufacturer’s instructions using Human serum albumin (HSA), 
Nerve growth factor (NGF) to generate standard curves. 
NGF encapsulated in the microspheres was quantified by specific 
immunoenzymatic assay ELISA (Enzyme-linked immunosorbent assay), 
according to the procedure recommended by the manufacturer (RayBio 
Human Beta-NGF ELISA Kit). The standard solution of NGF or the sample 
to be analyzed to appropriately diluted unknown concentration (100 μL) were 
added to each well of the multiwell plate coated with a specific monoclonal 
antibody of NGF. The loaded plate was incubated for 2.5 hours at room 
temperature and then washed 4 times with a washing solution (Wash 
Solution). Following the wash, we proceed with the addition of 100 μl of 
biotinylated antibody to each well. The plate is maintained in incubation at 
room temperature for 1 hours and then, after three washes, to each well to be 
analyzed is adds the TMB One-Step Substrate Reagent. After another 30 
minutes of incubation at room temperature in the dark with gentle shaking, to 
each well is adds50 μl of Stop Solution. The optical absorbance was 
measured by spectrophotometer (PelkinElmer) to the wavelength λ = 450nm. 
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2.2.4. “In vitro” release Kinetics 
In vitro release studies of NGF were made by suspending 20 mg of 
lyophilized microparticles containing  NGF fluorescein-labeled (theoretical 
loading 0.0098%)  in 1 ml of PBS pH 7.4, previously filtered through filter 
pores of 0.22 μm in diameter (Millex®, Millipore, USA). The samples were 
incubated in a incubator at 37°C and 30 RPM. for mimic the conditions of 
release. At regular intervals of time, the samples were centrifuged at 3000 
rpm for 5 minutes at 4 °C and the release media removed and replaced with 
the same volume of fresh PBS pH 7.4. The samples were analyzed by 
spectrofluorimeter (λmax=492nm) to determine the amount of  nerve growth 
factor released. 
 
 
2.3. PLGA nanoparticles for controlled release of NGF 
The PLGA nanoparticles containing NGF were prepared by the technique of 
multiple emulsion/solvent evaporation (W/O/W) with a theoretical loading 
0.0065% (0.065 mg to 100 mg of NGF microparticles). Briefly, a sterile 
buffer solution containing Nerve Growth Factor (conc. 0.98mg/ml) and 
Vitamin E in the ratio 1:1 (v/v) was emulsified by homogenization at 17.500 
rpm for 1 minutes (Ultraturrax T25 Basic, probe 8G, IKA, Germany), in 5 ml 
of a solution of PLGA and Poloxamer 188 (ratio 2:1) in Ethyl Acetate (1.5% 
w/v). The emulsion thus obtained was added  to the external phase consisting 
of 5 ml of an aqueous PVA solution (2% w/v) (Mowiol® 40-88) doped with 
300 µl of Ethyl Acetate, and emulsified by homogenization at 21.500 rpm for 
1 minutes. At the end, this double emulsion was added to trehalose water 
solution (5% w/v) and subjected to agitation by electronic stirrer (RZR 2102, 
Heidolph, Germany), at 500 rpm for 2.5 hours, at room temperature, in order 
to facilitate the evaporation of the organic solvent and the precipitation of the 
 107 
 
polymer in the form of nanoparticles. Thereafter, the microparticles were 
isolated and washed with 30 ml of distilled water 2 times, by centrifugation at 
12000 rpm for 10 minutes at 4⁰C and subsequently subjected to a 
lyophilization cycle of 24 hours (0,001 atm , -60°C ) (Freeze Dryer Alpha 1-4 
LD plus, Martin Christ, DE). 
2.3.1. Dimensional and Morphological analysis of nanoparticles 
 
a) Osservazione al microscopio a trasmissione elettronica (TEM) 
The morphology of the nanoparticles was analyzed with the aid of a 
Transmission Electron Microscope (TEM) (Tecnai FEI, Eindhoven, 
Netherlands). Briefly, 10 μl of a suspension of nanoparticles (1 mg/ml) were 
laid on a 300 mesh copper grid with membrane Lacey Carbon, specific 
support for analysis by TEM. The nanoparticles were subsequently treated 
with phosphotungstic acid (2% w/v), the support was dried at room 
temperature and analyzed. 
b) Analysis of the size and  potential  
The dimensions and the ζ potential of the nanoparticles obtained with the two 
different protocols were determined by a Zetasizer® Nano (Malvern 
Instruments, UK). In particular, the dimensions have been assessed using the 
technique of Photon Correlation Spectroscopy (PCS), analyzing Doppler 
Anemometry (LDA), appropriate dilution of the sample with a salt solution 
KCl 1N. 
 
2.3.2. Encapsulation efficacy 
The encapsulation efficiency of NGF in the nanoparticles was determined by 
extraction of the protein in ethyl acetate/Buffer solution, as described 
previously for the microparticles. Briefly, 10 mg of lyophilized nanoparticles 
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was solubilized in 1 ml of ethyl acetate, and NGF was extracted with 1 ml of 
Buffer solution (50 mM NaH2PO4 .H2O, 100 mM NaCl, pH 7.2). Following 
quantitative determination by spectrofluorometric assay (FluoroProfile Kit, 
Sigma Aldrich). 
 
2.3.3. “In vitro” release kinetics 
The profiles of in vitro release of NGF from PLGA and Poloxamer based 
nanoparticles was determined by incubating 5 ml of a suspension 
nanoparticles (2 mg/ml), at 37 ° C in static conditions. At intervals of time 
regular, 500 μl of this suspension were collected, filtered through filters with 
porosity of 0.22 μM and analyzed by FluoroProfile Kit, as previously 
described. The total volume of the release media was restored with fresh PBS 
pH 7.4 at each time interval. 
2.3.4. Freeze-drying Studies of nanoparticles 
There is strong evidence that nanoparticles in aqueous media form colloidal 
suspensions that have a limited stability over time. In order to increase the 
stability and to simplify the conservation of these particle systems have been 
conducted studies of lyophilization of nanoparticulate suspensions, 
containing NGF and white, in the presence of cryoprotectants of sugar nature, 
in particular trehalose and sucrose. 
The nanoparticles were suspended in an aqueous solution containing 
trehalose or sucrose at 5% (w/v). The studies were conducted using 
suspensions of nanoparticles at the concentration of 1mg/ml. The suspension 
obtained was frozen at -80 ° C and subjected to a cycle of lyophilization of 
about 48 hours. The lyophilized powder was resuspended in water filtered 
and appropriately diluted in order to be analyzed by Zetasizer® Nano 
(Malvern Instruments, UK), in order to assess the size and the polydispersity 
index. 
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3. Results and Discussions 
3.1.  Properties of microparticles containing Nerve Growth Factor 
The most common techniques used for the preparation of microparticles 
provide the formation of emulsions between aqueous phases containing the 
bioactive agents and an organic phase containing the polymer. A good 
process should lead to microparticles formulation with a high encapsulation 
efficiency, desired size, and with a sustained release kinetics. Furthermore, 
the encapsulated bioactive agent must maintain its stability. This is 
particularly important when the active agent is a growth factor. In fact, if the 
growth factor is denatured during the formulation process, it will be 
therapeutically inactive, and might cause unpredictable side effects, such as 
immunogenicity or toxicity
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. 
The most used organic solvent in double emulsion technique is methylene 
chloride (MC), however, evidence of stability of NGF in different solvents 
has detected that the MC leads to a loss of activity of about 20-30%. To solve 
this problem it was used ethyl acetate (EA) as organic solvent for the process 
of double emulsion. Compared to the more hydrophobic MC, EA usually 
plays a less deteriorative effect on bioactivity of the entrapped proteins. So 
far, only protein C has been found more sensitive to EA than to MC. 
However, most researchers in this field still choose MC as the organic 
solvent because of its desirable physical properties, such as ability to dissolve 
large amounts of biodegradable polymers, low solubility in water (2.0%, w/v) 
and low boiling point convenient to be removed by evaporation (39.8 °C). In 
contrast, the relatively high solubility in water (8.7%, w/v) and the high 
boiling point (76.7 °C) of EA limited its application in W/O/W double 
emulsion technique. The relatively high solubility of EA in water usually 
gives rise to a fast diffusion of EA from oil droplets into the outer aqueous 
phase during the re-emulsification and solidification, which easily leads to 
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polymer precipitation rather than the formation of microparticles. On the 
other hand, the higher boiling point indicates a longer removal time to 
solidify microparticles by evaporation, which means a longer contact time 
between proteins and ethyl acetate, resulting in more loss in protein 
bioactivity
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.  
To further improve the stability of the NGF different stabilizing agents were 
added to the aqueous phase containing the growth factor: Polyetilenglycole 
400 (PEG400), Human serum Albumin (HSA), Heparin (hp) and Vitamin E 
TPGS.  
The PEG400 and HSA were identified as a stabilizing agents because with 
their amphiphilic properties, preserves the growth factor from the aggregation 
to the water/oil during the process of emulsification (sacrificial lamb 
approach). Instead, the heparin interacting with the specific binding domain 
present on growth factors (Hp binding domain), stabilizes the active three-
dimensional structure of the macromolecule and promotes its interaction with 
specific receptors located on cell membranes. Finally, the Vitamin E TPGS is  
a water-soluble source of vitamin E, that presents a structure consisting of a 
lipophilic and a hydrophilic portion, therefore results to have remarkable 
amphiphilic properties. Moreover, its lipophilic alkyl tail (polyethylene 
glycol) and hydrophilic polar head portion (tocopherol succinate) are bulky 
and have large surface areas. The hydrofile-lipophile balance (HLB) of TPGS 
is about 13 and it melts at 37–41 °C and is heat stable under temperature 
200°C. Such characteristic makes it a good emulsifier able to minimize the 
interactions between the aqueous phase containing the growth factor and the 
oil phase containing the polymers. In addition, numerous studies have 
demonstrated the remarkable antioxidant ability of this vitamin and its 
beneficial effects on Age-related Macular Degeneration (AMD). 
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The properties of the formulations of microparticles produced are shown in 
Table 9.   
Type Excipients 
Microparticles 
average diameter 
(µm ± S.D.) 
Total Protein 
Encapsulation 
Efficency (% ± 
D.S.) 
NGF 
Encapsulation 
Efficiency 
(% ± D.S.) 
Micro A HSA, PEG400 3.5 ± 1 76 ± 3.4 30.2 ± 6.4 
Micro B 
Heparin, 
HSA and PEG400 
5.2 ± 1 64.1 ± 1.7 27.8 ± 1.4 
Micro C Vitamin TPGS 8.0 ± 1 ------------- 29.3 ± 2.8 
Micro D --------- 13.6 ± 1 ------------- 2 ± 2.9 
Table 9 : Properties of microparticles containing NGF 
 
From the results shown in Table 9, it is possible to observe that the addition 
of stabilizing agents greatly increase the efficiency of encapsulation (about 
30%) compared to control (about 2%), confirming the hypothesis previously 
expressed.   
The particles prepared by encapsulating BSA and NGF labeled with 
fluorescent probes, respectively BSA rhodamine-labeled (BSA-Rhod) and  
NGF fluorescein-labeled (Fluo-NGF), were analyzed by confocal microscopy 
(Leica, TCS SP5 II), in order to observe the distribution of molecules within 
the microparticles. The analysis shows that the NGF is uniformly distributed 
throughout the volume of the microparticle (green signal) and that the HSA 
(red signal) is distributed mainly on the surface of the interior cavities of the 
microparticle (Fig. 31). 
 112 
 
 
Figure 31 : Confocal image of microparticles containing BSA-Rhod and NGF-Fluo 
 
Finally, As shown in the micrographs (Fig. 32) the formulation conditions of 
the microparticles have been optimized in order to obtain particles with a 
diameter smaller to 10 µm, such that they can diffuse into the vitreous humor 
without affecting the vision . 
 
Figure 32 : Micrographs of different type of microparticles : (A)MS(with Vitamin E TPGS, (B) MS 
with HSA and PEG400, (C) MS with HSA,Hp and PEG400 
 
3.1.1. Nerve Growth Factor release kinetics from microparticles 
The kinetics of in vitro release of NGF from the microparticles was evaluated 
in PBS pH 7.4, at 37 ° C, under static conditions. Taking into account the 
different properties of the microparticles studied, has been conducted the 
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study on the kinetics of release of NGF only for the formulation Micro A, 
characterized by the best encapsulation efficiency. 
The release profile of NGF from the microparticles is shown in figure X, 
expressed as µg of NGF released in active form for 1 mg of microparticles as 
a function of time. As can be seen from the figure, the microparticles show an 
fast initial release of NGF, in the first day of incubation, followed by a 
sustained controlled release of 37 ng\mg NGF throughout the period under 
consideration. 
 
 
Figure 33 :  Release profile of NGF from PLGA-based micrparticles in PBS pH 7.4 a 37°C. The 
results were expressed as µg NGF released per 1 mg of microparticles, mean ± SD of three replicates 
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3.2. Properties of nanoparticles containing Nerve Growth Factor 
Nanoparticle-based blend of PLGA/Poloxamer, containing NGF were 
prepared using the modified technique of emulsion/solvent diffusion. This 
technique, although it is the most widely used for the fabrication of micro-
and nanoparticles, may include some risk for the activity of growth factors 
such as NGF.  In fact, the formation of an emulsion between the aqueous 
phase containing the active principle and the organic phase containing the 
mixture of polymers, can promote the localization of the GF to the water/oil 
interface, minimizing the mobility of the molecule and favoring  the 
aggregation phenomena. On the other hand, the biodegradation of the PLGA 
involves the formation of water-soluble derivatives of acidic nature, 
responsible for the fall of the pH value within the nanoparticles. Furthermore, 
the anionic nature of the PLGA used in the preparation of such nanosystems 
can promote the formation of undesired interactions polymer/protein. These 
phenomena not only affect the characteristics of the control of the release of 
active principle, but may alter the native structure of the macromolecule 
leading to a loss of the activity of GFs.  
In order to minimize these risks, it was decided to add an excipient to the 
polymer phase: the poloxamer 188. Several studies have shown that this 
excipient having a stabilizing activity when encapsulated within nanoparticle 
systems. Further studies have shown that the poloxamer 188 is able to 
minimize the iterations between the carboxylic residues of PLGA and the 
growth factor encapsulated and is also able to reduce the effects of the 
decrease of the pH of the microenvironment due to the degradation of PLGA. 
Finally, studies conducted on PLGA\Poloxamer 188 nanoparticles containing 
nucleic acids have shown that the presence of poloxamer on their surface 
results in a reduction of the negative charges of the surface which results in a 
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lessening of the phenomena of particle aggregation and phagocytosis by 
macrophages. 
Beside the use of poloxamer 188, which further strategy stabilizer, the NGF 
has been encapsulated together with vitamin E TPGS, a water-soluble source 
of vitamin E previously described. 
the analysis of the morphology obtained by transmission electron microscopy 
(TEM) showed that the nanoparticles prepared are spherical, characterized by 
a regular morphology and a smooth surface, in agreement with particles 
usually obtained from such preparation technique (Fig. 34).  This aspect is of 
particular importance considering the prospect of use of these nanoparticles 
as controlled release systems of NGF to eye level. 
  
Figure 34 : Microgrphs at different magnification of nanoparticle containing NGF 
From the results shown in Table X it is possible to observe that while varying 
the ratio between PLGA and poloxamer 188 in the oil phase, the particles do 
not exhibit significant differences in the values of average diameter, 
polydispersity index and production yield, resulting in all cases in agreement 
with the properties of nanoparticles based on PLGA/Poloxamer prepared by 
the same technique formulation. Such systems, in fact, generally show 
average diameters less than 300 nm, and polydispersity indices of about 0.1. 
 116 
 
Type 
PLGA/
Pol 
188 
Ratio 
Encapsulation 
Efficancy  
( % ± D.S.) 
production yield  ( % 
± D.S.) 
ζ 
Potential 
 ( mV ± 
D.S.) 
SIZE 
 ( nm ± 
D.S.) 
PDI 
Nano 
A 
5:1 33.4 ± 2 79 ± 2 
-30.3 ± 
1.6 
239.8 ± 1 
0.026 - 
0.032 
Nano 
B 
3:1 31.1 ± 1 74 ± 4 
-30.1 ± 
1.8 
233.4 ± 1 
0.066 - 
0.071 
Nano 
C 
2:1 30.3 ± 2 78 ± 2 
-31.2 ± 
1.3 
226.4 ± 1 
0.055 - 
0.060 
Table 10 : Properties of nanoparticles containing NGF 
 
The efficiency of encapsulation remains more or less unchanged at around a 
value of about 31%. These values are in agreement with those obtained from 
the microparticles, confirming the hypothesis that the use of ethyl acetate in 
the formulation decreases the efficiency of the process of the double 
emulsion/solvent evaporation. We note that the decrease of the ratio between 
PLGA and Poloxamer also decreases the efficiency of encapsulation. This 
may be attributable to the fact that decreasing the amount of poloxamer 
increases the share of the growth factor in contact with the oil phase. 
 
3.2.1. Nerve Growth Factor release kinetics from nanoparticles 
The release profiles of NGF, respectively from the formulations Nano A, 
Nano B and C, were obtained by suspending the nanoparticles in PBS pH 7.4 
and incubating the samples at 37 ° C in static conditions. 
All formulations show an initial release of the GF (burst) of approximately 
33% of the total amount encapsulated in the nanoparticles. Burst so high are 
typical of formulations based on PLGA by nanometric dimensions. The first 
phase of the release is dominated, in fact, by means of dissolution in the 
release of the protein located on the surface of the particle and/or macropores 
internal to it. Being nanometric systems, the surface exposed to the release 
media is particularly large, therefore the diffusion of the GF is favored, thus 
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achieving relatively higher proportions in the first hours of incubation. At the 
initial burst, however, follows a sustained release for the whole period 
examined (Fig. X). 
 
Figure 35 : Release profile of NGF from  all type of PLGA-based nanoparticles in PBS pH 7.4 a 
37°C. The results were expressed as µg NGF released per 1 mg of microparticles, mean ± SD of 
three replicates 
 
3.2.2. Freeze-drying Studies of nanoparticles 
In order to prolong the stability of the nanoparticles in suspension, 
lyophilization studies have been conducted  in the presence of trehalose and 
sucrose at 5% w/v. The use of a cryoprotectant is essential during the process 
of freezing and lyophilization to avoid phenomena of nanoparticles 
aggregation.  
The lyophilization studies were conducted on a suspension of 1mg/ml of 
nanoparticles in all three formulations. The lyophilized powders obtained 
were suspended in water and analyzed by Zetasizer® Nano to assess the size 
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and polydispersity index (PI) after the lyophilization process. The results 
obtained are depicted in the graph X and Y. 
 
Figure 36 : Studies of freeze/drying of nanoparticles containing NGF in the presence of Sucrose 5% 
w/v. 
 
 
Figure 37 : Studies of freeze-drying of nanoparticles containing NGF in the presence of trehalose 
5% w/v 
From the graphs we can see that the size and PDI of lyophilized formulations 
have a slight increase compared to the control formulations. These increases, 
however, are not indicative of a phenomenon of aggregation, suggesting that 
the original features of the lyophilized formulations remain almost 
unchanged, in all cases analyzed. 
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From the graphs it is also noted that there isn’t significant difference between 
freeze-dried samples in the presence of trehalose and sucrose, demonstrating 
that both sugars are excellent cryoprotectant agents. Nevertheless, the 
trehalose remains the cryoprotectant elected for subsequent studies of 
lyophilization, not only for the excellent results obtained, but also because 
appears  to be one of the more inert and most used excipients. 
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4. Conclusions 
An intraocular drug delivery systems for the controlled release of growth 
factors for the treatment of different ocular diseases is proposed in this work. 
The traditional treatment of these pathologies consists of daily administration 
of drugs, but, the main limit of these conventional treatments is bound to the 
fact that blood levels of the drug falling into the therapeutic range are 
obtained right after administration. In other words, there is a risk that the 
drug action lasts too little to have a significant effect on the patient.  
To overcome these issues and to optimize the clinical performance we have 
developed PLGA micro e nanoparticles system for the controlled release of a 
specific factor: Nerve Growth Factor (NGF) to the humor vitreous. This 
factor has been shown to have a protective effect on the cells of the visual 
system, opening interesting therapeutic prospects for degenerative diseases 
currently no effective treatments, such as the age-related macular 
degeneration, diabetic retinopathy, retinitis pigmentosa and glaucoma. 
We demonstrated that the encapsulation efficiency could be increased by 
adding water-soluble excipients to the inner aqueous phase prior to 
emulsification. In particular, have been used and evaluated different 
excipients such as the HSA for microparticulate systems and Vitamin E 
TPGS for nanoparticle systems. 
We showed that encapsulation of NGF in PLGA particles provides a 
sustained release formulation, maintaining concentrations of the 
macromolecule at pico/nanomolar levels. The micro-and nanoparticles 
developed, keep a control of the concentration of growth factor constant in 
time by daily doses of approximately 37 ng/mg for microparticles and 
0.3ng\mg for nanoparticles 
Taking into account that doses of factor excessive or uncontrolled may cause 
side effects, an important result of this study is that particle systems for the 
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controlled release of NGF are capable of providing a slow and sustained 
release of the active, allowing to obtain a cellular response to NGF better 
than simply dispersed and at higher concentrations. 
These results demonstrate that NGF-containing in micro e nanoparticles are 
an effective means for delivering this molecule into the eye and their use may 
be a promising strategy in the treatment of different ocular disease 
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